WO2013152252A1 - Polythérapie antinéoplasique - Google Patents

Polythérapie antinéoplasique Download PDF

Info

Publication number
WO2013152252A1
WO2013152252A1 PCT/US2013/035358 US2013035358W WO2013152252A1 WO 2013152252 A1 WO2013152252 A1 WO 2013152252A1 US 2013035358 W US2013035358 W US 2013035358W WO 2013152252 A1 WO2013152252 A1 WO 2013152252A1
Authority
WO
WIPO (PCT)
Prior art keywords
igf
kinase inhibitor
met
kinase
cancer
Prior art date
Application number
PCT/US2013/035358
Other languages
English (en)
Inventor
Elizabeth A. Buck
John D. Haley
Stuart Thomson
Mark J. Mulvihill
David M. Epstein
Mark R. Miglarese
Original Assignee
OSI Pharmaceuticals, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSI Pharmaceuticals, LLC filed Critical OSI Pharmaceuticals, LLC
Publication of WO2013152252A1 publication Critical patent/WO2013152252A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the present invention is directed to compositions and methods for treating cancer patients.
  • Cancer is a generic name for a wide range of cellular malignancies characterized by unregulated growth, lack of differentiation, and the ability to invade local tissues and metastasize. These neoplastic malignancies affect, with various degrees of prevalence, every tissue and organ in the body.
  • DNA-alkylating agents e.g., cyclophosphamide, ifosfamide
  • antimetabolites e.g., methotrexate, a folate antagonist, and 5-fluorouracil, a pyrimidine antagonist
  • microtubule disrupters e.g., vincristine, vinblastine, paclitaxel
  • DNA intercalators e.g., doxorubicin, daunomycin, cisplatin
  • hormone therapy e.g., tamoxifen, flutamide.
  • gene targeted therapies such as protein-tyrosine kinase inhibitors (e.g. imatinib; the EGFR kinase inhibitor, erlotinib) have increasingly been used in cancer therapy.
  • An anti -neoplastic drug would ideally kill cancer cells selectively, with a wide therapeutic index relative to its toxicity towards non-malignant cells. It would also retain its efficacy against malignant cells, even after prolonged exposure to the drug. Unfortunately, none of the current chemotherapies possess such an ideal profile.
  • cancerous cells exposed to slightly sub-lethal concentrations of a chemotherapeutic agent will very often develop resistance to such an agent, and quite often cross-resistance to several other antineoplastic agents as well.
  • newer gene-targeted therapies such as EGFR kinase inhibitors, thus necessitating considerable trial and error, often at considerable risk and discomfort to the patient, in order to find the most effective therapy.
  • the efficacy of the drug combination is additive (the efficacy of the combination is approximately equal to the sum of the effects of each drug alone), but in other cases the effect is synergistic (the efficacy of the combination is greater than the sum of the effects of each drug given alone).
  • IGF-1R is a transmembrane RTK that binds primarily to IGF-1 but also to 1GF- II and insulin with lower affinity. Binding of IGF-1 to its receptor results activation of receptor tyrosine kinase activity, intermolecular receptor autophosphorylation and phosphorylation of cellular substrates (major substrates are IRS1 and She).
  • the ligand- activated IGF-1R induces mitogenic activity in normal cells and plays an important role in abnormal growth.
  • a major physiological role of the IGF-1 system is the promotion of normal growth and regeneration.
  • Overexpressed IGF-1R (type 1 insulin- like growth factor receptor) can initiate mitogenesis and promote ligand-dependent neoplastic transformation.
  • IGF-1R abrogates progression into apoptosis, both in vivo and in vitro. It has also been shown that a decrease in the level of IGF-1R below wild-type levels causes apoptosis of tumor cells in vivo. The ability of IGF-1 R disruption to cause apoptosis appears to be diminished in normal, non-tumorigenic cells.
  • the IGF-1 pathway in human tumor development has an important role. IGF- IR overexpression is frequently found in various tumors (breast, colon, lung, sarcoma) and is often associated with an aggressive phenotype. High circulating IGF1 concentrations are strongly correlated with prostate, lung and breast cancer risk.
  • IGF-IR is required for establishment and maintenance of the transformed phenotype in vitro and in vivo (Baserga R. Exp. Cell. Res., 1999, 253, 1-6).
  • the kinase activity of IGF-IR is essential for the transforming activity of several oncogenes: EGFR, PDGFR, SV40 T antigen, activated Ras, Raf, and v-Src.
  • the expression of IGF-IR in normal fibroblasts induces neoplastic phenotypes. IGF-IR expression plays an important role in anchorage-independent growth. IGF-IR has also been shown to protect cells from chemotherapy-, radiation-, and cytokine-induced apoptosis.
  • inhibitors of protein-tyrosine kinases are useful as selective inhibitors of the growth of mammalian cancer cells.
  • GleevecTM also known as imatinib mesylate
  • a 2-phenylpyrimidine tyrosine kinase inhibitor that inhibits the kinase activity of the BCR-ABL fusion gene product
  • the 4- anilinoquinazoline compound TarcevaTM (erlotinib HC1) has also been recently approved by the FDA, and selectively inhibits EGF receptor kinase with high potency.
  • Human IGFBP-3 is expressed in multiple tissues (e.g. liver) as a 291 amino acid precursor protein with a putative 27 amino acid signal peptide that is processed to generate a 264 amino acid mature protein with three potential N-linked and two potential O-linked glycosylation sites.
  • Human IGFBP-3 is the major IGF binding protein in plasma where it exists in a ternary complex with IGF-I or IGF-II and the acid-labile subunit (Jones, J.I. and D.R. Clemmons (1995), Endocrine Rev. 16:3;
  • MET i.e. c-Met
  • HGF hepatocyte growth factor
  • Such cancers include, but are not limited to, gastric adenocarcinoma, renal cancer, small cell lung carcinoma, colorectal cancer, prostate cancer, brain cancer, liver cancer, pancreatic cancer, and breast cancer.
  • Hepatocyte growth factor also known as scatter factor, is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and acts on epithelial cells, endothelial cells, and haemopoietic progenitor cells. It plays a major role in embryonic organ development, adult organ regeneration, and wound healing. It also promotes transformation, tumor development and metastasis by stimulating mitogenesis, cell motility and invasion via various signaling pathways. In order to produce cellular effects, HGF must bind to the MET receptor (i.e.
  • MET a receptor tyrosine kinase. This is a widely expressed heterodimeric protein comprising a 50 kilodalton (kDa) a-subunit and 145 kDa subunit ⁇ -subunit (Maggiora et al., J. Cell Physiol, 173: 183-186, 1997).
  • the MET receptor is is initially produced as a single- chain precursor, that is proteolytically cleaved at a furin site to yield the highly glycosylated extracellular a-subunit and the transmembrane ⁇ -subunit, which are linked together by a disulfide bridge.
  • EGFR, MET, IGF-IR, and IR are each sufficient for oncogenic transformation in vitro and in vivo (1-9). Inhibitors targeting each of these RTKs individually have shown efficacy in a wide range of preclinical models, and this has spurred their evaluation as anti-tumor therapeutics in the clinic (2, 4, 10-12).
  • Antibody or small molecule inhibitors of EGFR are clinically approved for the treatment of a number of tumor types including NSCLC (erlotinib), SCCHN (cetuximab), CRC (cetuximab / panitumumab), and pancreatic cancer (erlotinib) (13-16). Drug candidates targeting IGF-IR, IR, and MET are currently in advanced clinical development (17).
  • Compensatory crosstalk may occur within an RTK family. For example, there is evidence for bidirectional crosstalk between IGF-IR and IR, where blockade of either receptor is associated with a compensatory increase in activity through the reciprocal receptor (18). Compensatory crosstalk can also extend between different RTK families.
  • NSCLC tumor cells harboring primary activating mutations in EGFR exhibit elevated sensitivity to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib, however, acquired resistance following prolonged exposure to an EGFR TKI can be associated with increased dependence on MET (19-22).
  • This mode of resistance to EGFR inhibitors is especially prominent for tumors exhibiting genetic amplification of the MET loci (23, 24).
  • WT wild-type
  • IGF-IR/IR signaling can confer acquired resistance, where prolonged exposure to agents targeting either EGFR or IGF-IR/IR may be associated with an increased dependence on signaling through the reciprocal receptor (25, 26).
  • IGF-1R kinase inhibitors for use such combinations include a new class of relatively specific, orally- available, small-molecule IGF-1R kinase inhibitors that also inhibit IR kinase (e.g. OSI-906, (a.k.a. linsitinib)), or alternatively, small-molecule IGF-1R kinase inhibitors that also inhibit MET kinase may be used, thus precluding the need for a separate MET kinase inhibitor.
  • IR kinase e.g. OSI-906, (a.k.a. linsitinib)
  • small-molecule IGF-1R kinase inhibitors that also inhibit MET kinase may be used, thus precluding the need for a separate MET kinase inhibitor.
  • the present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of a MET kinase inhibitor and an IGF-IR kinase inhibitor.
  • the IGF-IR kinase inhibitor may be a small- molecule IGF-IR kinase inhibitor, such as those of Formula (I) (e.g.OSI-906), an anti- IGF-1R antibody or antibody fragment, or one or more IGF binding proteins that antagonizes activation of IGF-IR.
  • the combined IGF-IR kinase and MET kinase inhibitory activities may reside in the same molecule, e.g.
  • IGF-IR kinase inhibitor that also has inhibitory activity on MET kinase (i.e. a dual IGF-IR kinase/MET kinase inhibitor), thus precluding the need for a separate MET kinase inhibitor.
  • the IGF-IR kinase inhibitor of Formula (I) can be any IGF-IR kinase inhibitor compound encompassed by Formula (I) that inhibits IGF-IR kinase upon
  • IGF- 1 R kinase inhibitor of Formula (I) is represented by the formula:
  • Xi, and X 2 are each independently N or C-(E 1 ) aa ;
  • X 5 is N, C-(E l ) aa , or ⁇ 1 ) ⁇
  • X 3 , X 4 , X 6 , and X 7 are each independently N or C; [22] wherein at least one of X 3 , X 4 , X 5 , X 6 , and X 7 is independently N or N-(E 1 ) aa ;
  • Xn, Xi 2 , Xi3, Xi4, Xi5, and Xi 6 are each independently N, C-(E u ) b b, or N + -0 " wherein at least one of Xn, Xi 2 , X13, X14, X15, and Xi 6 is N or N + -0 " ;
  • R 1 is absent, Co-ioalkyl, cycloC 3 _ioalkyl, bicycloC 5 _ioalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterobicycloCs-ioalkyl, spiroalkyl, or
  • heterospiroalkyl any of which is optionally substituted by one or more independent G 11 substituents;
  • E 1 , E 11 , G 1 , and G 41 are each independently halo, -CF 3 , -OCF3, -OR 2 ,
  • Ci_ioalkylidene C 0 -i 0 alkyl, C 2 _i 0 alkenyl, C 2 _i 0 alkynyl, Ci_i 0 alkoxyCi_ l oalkyl, Ci_ioalkoxyC 2 _ioalkenyl, Ci_ioalkoxyC 2 _ioalkynyl, Ci_ioalkylthioCi_ioalkyl, Ci_ ioalkylthioC 2 _ioalkenyl, Ci_ioalkylthioC 2 _ioalkynyl, cycloC 3 - 8 alkyl, cycloC 3 _ 8 alkeny
  • G 11 is aryl-Co-ioalkyl, aryl-C 2 _ioalkenyl, aryl-C 2 _ioalkynyl, hetaryl-Co- l oalkyl, hetaryl-C 2 _ioalkenyl, or hetaryl-C 2 _ioalkynyl, any of which is optionally substituted with one or more independent halo, -CF 3 , OR 2221
  • R 333al are each independently Co_ioalkyl, C 2 _ioalkenyl, C 2 _ioalkynyl, Ci_ioalkoxyCi_ l oalkyl, Ci_ioalkoxyC 2 _ioalkenyl, Ci_ioalkoxyC 2 _ioalkynyl, Ci_ioalkylthioCi_ioalkyl, Ci_ ioalkylthioC 2 _ioalkenyl, Ci_ioalkylthioC 2 _ioalkynyl, cycloC 3 _ 8 alkyl, cycloC 3 _ 8 alkenyl, cycloC 3 _ 8 alkylCi_ioalkyl, cycloC 3 - 8 alkenylCi_ioalkyl, cycloC 3 _ 8 alkylC 2 _ioalkenyl, cycloC 3 _ 8 alkenylC
  • R 2 and R 3 , or R 222 and R 333 , or R 2221 and R 3331 are optionally taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted by one or more independent G 1111 substituents and wherein said ring optionally includes one or more heteroatoms other than the nitrogen to which R 2 and R 3 , or R 222 and R 333 , or R 2221 and R 3331 are optionally taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted by one or more independent G 1111 substituents and wherein said ring optionally includes one or more heteroatoms other than the nitrogen to which R 2 and R 3 , or R 222 and R 333 , or R 2221 and R 3331 are
  • W 1 and Y 1 are each independently -0-, -NR 7 -, -S(0) j7 - -CR 5 R 6 -,
  • R 5 , R 6 , G 111 , and G 1111 are each independently C 0 -i 0 alkyl, C 2 _i 0 alkenyl, C 2 _ l oalkynyl, Ci_ioalkoxyCi_ioalkyl, Ci_ioalkoxyC 2 _ioalkenyl, Ci_ioalkoxyC 2 _ioalkynyl, Ci_ioalkylthioCi_ioalkyl, Ci_ioalkylthioC 2 _ioalkenyl, Ci_ioalkylthioC 2 _ioalkynyl, cycloC 3 _ 8 alkyl, cycloC 3 _ 8 alkenyl, cycloC 3 _ 8 alkylCi_ioalkyl, cycloC 3 _ 8 alkenylCi_ioalkylC 2 _ioalkylC 2 _ioalkyl,
  • R 5 with R 6 are optionally taken together with the carbon atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted with one or more independent R 69 substituents and wherein said ring optionally includes one or more heteroatoms;
  • R 7 , R 7a , and R 8 are each independently acyl, C 0-10 alkyl, C 2 _ioalkenyl, aryl, heteroaryl, heterocyclyl or cycloC 3 _ioalkyl, any of which is optionally substituted by one or more independent G 111 substituents;
  • R 4 is Co-ioalkyl, C 2 _ioalkenyl, C 2 _ioalkynyl, aryl, heteroaryl, cycloC 3 _ioalkyl, heterocyclyl, cycloC 3 _ 8 alkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G 41 substituents;
  • R 69 is aryl-Co-ioalkyl, aryl-C 2 _ioalkenyl, aryl-C 2 _ioalkynyl, hetaryl-Co- l oalkyl, hetaryl-C 2 _ioalkenyl, hetaryl-C 2 _ioalkynyl, mono(Ci_ 6 alkyl)aminoCi_ 6 alkyl, di(Ci_ 6 alkyl)aminoCi_ 6 alkyl, mono(aryl)aminoCi_ 6 alkyl, di(aryl)aminoCi_ 6 alkyl, or -N(Ci_ 6 alkyl)-Ci_ 6 alkyl-aryl, any of which is optionally substituted with one or more independent halo, cyano, nitro, -OR 778 , Ci_ioalkyl, C 2 _ioalkenyl, C 2 _ioal
  • R and R are optionally taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, Ci_i 0 alkoxy, -S0 2 NR 778 R 888 , or -NR 778 R 888 substituents, and wherein said ring optionally includes one or more heteroatoms other
  • R 77 , R 78 , R 87 , R 88 , R 778 , and R 888 are each independently C 0 -i 0 alkyl, C 2 -i 0 alkenyl, C 2 _ioalkynyl, Ci_ioalkoxyCi_ioalkyl, Ci_ioalkoxyC 2 _ioalkenyl, Ci_ioalkoxyC 2 _ioalkynyl, Ci_ioalkylthioCi_ioalkyl, Ci_ioalkylthioC 2 _ioalkenyl, Ci_ioalkylthioC 2 _ioalkynyl, cycloC 3 _ 8 alkyl, cycloC 3 _ 8 alkenyl, cycloC 3 _ 8 alkylCi_ioalkyl, cycloC 3 - 8 alkenylCi_ioalkyl, cycloC 3 - 8
  • Ci_ioalkoxycarbonyl Ci_ioalkoxycarbonylCi_ioalkyl, monoCi_ 6 alkylaminocarbonyl, diC i_ 6 alkylaminocarbonyl, mono(aryl)aminocarbonyl, di(aryl)aminocarbonyl, or Ci_ioalkyl(aryl)aminocarbonyl, any of which is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, Ci_ioalkoxy, -S0 2 N(Co- 4 alkyl)(C 0 - 4 alkyl), or -N(C 0 - 4 alkyl)(C 0 - 4 alkyl) substituents;
  • R 77 , R 78 , R 87 , R 88 , R 778 , and R 888 are each independently aryl-C 0 -i 0 alkyl, aryl-C 2 _ioalkenyl, aryl-C 2 _ioalkynyl, hetaryl-Co_ioalkyl, hetaryl-C 2 _ioalkenyl, hetaryl-C 2 _ioalkynyl, mono(C i_ 6 alkyl)aminoC i_ 6 alkyl, di(C i_ 6 alkyl)aminoC i_ 6 alkyl, mono(aryl)aminoCi_ 6 alkyl, di(aryl)aminoCi_ 6 alkyl, or -N(Ci_ 6 alkyl)-Ci_ 6 alkyl-aryl, any of which is optionally substituted with one or more independent halo, cyano
  • n, m, j l, j la, j2a, j4, j4a, j5a, j7, andj8 are each independently 0, 1, or 2; and aa and bb are each independently 0 or 1.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising an MET kinase inhibitor and an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)), in a pharmaceutically acceptable carrier.
  • an IGF-IR kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • the present invention also provides a kit comprising one or more containers, comprising an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)), and an MET kinase inhibitor.
  • an IGF-IR kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • MET kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • a pharmaceutical composition comprising a MET kinase inhibitor and an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)), in a pharmaceutically acceptable carrier.
  • the present invention also provides a kit comprising one or more containers, comprising a MET kinase inhibitor and an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)).
  • a MET kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • an IGF-IR kinase inhibitor of Formula (I) e.g. an IGF-IR kinase inhibitor of Formula (I)
  • the patient may be a patient in need of treatment for cancer.
  • the cells of the tumors or tumor metastases may be relatively insensitive or refractory to treatment with one of the anticancer agents (i.e. the MET kinase inhibitor or the IGF-IR kinase inhibitor) as a single agent.
  • the anticancer agents i.e. the MET kinase inhibitor or the IGF-IR kinase inhibitor
  • FIG. Coordinated expression and phosphorylation of receptors within the EGF, HGF, and IGF axes.
  • A Heat map showing correlative expression of mRNAs fori 8 RTKs within a human tumor database comprised of NSCLC, CRC, SCCHN, and OvCa tumors (left panel). Heat may showing co-correlative expression of mRNA for IR, MET, and EGFR within the human tumor database, anchored on INSR expression (right panel). Pearson correlation coefficients which reached significance are shown.
  • B RTK arrays for a select group of human tumor cell lines showing the phosphorylation pattern for EGFR, MET, IR, and IGF-IR (left panel). Within a group of 35 tumor cell lines, seven exhibit concurrent expression of phospho-EGFR, phospho-IGF-lR/IR, and phospho-MET and are all sensitive to OSI-906 (right panel).
  • FIG. 1 Either EGF or HGF can rescue phospho-AKT/PRAS40, proliferation, and survival in tumor cells treated with OSI-906, alone or in combination with erlotinib.
  • A. Effect of OSI-906 ( ⁇ ), erlotinib ( ⁇ ⁇ ), or the combination of OSI-906 and erlotinib on phospho-A T/PRAS40 under either basal (10% FCS), EGF(50ng/ml), or HGF(100ng/ml) conditions.
  • B Effect of varying concentrations of OSI-906 on cellular proliferation under basal conditions or in the presence of HGF (left panel).
  • Figure 3 The combination of a MET TKI and OSl-906, but not an IGF-1R specific antibody, results in synergistic inhibition of cell proliferation and AKT signaling.
  • A Effect of PHA ( ⁇ ⁇ ), OSl-906 ( ⁇ ⁇ ), or erlotinib ( ⁇ ⁇ ) on cell proliferation for GEO tumor cells under basal or HGF -treated conditions (top panel). Effect of varying concentrations of OSl-906, alone or in the presence of PHA, on cell proliferation for GEO tumor cells cultured in the presence of HGF (bottom panel).
  • PHA ⁇ ⁇
  • OSl-906 ⁇ ⁇
  • erlotinib ⁇ ⁇
  • OSl-906, PHA, or OSl-906 + PHA on phospho- AKT/PRAS40 and phospho-ERK for GEO tumor cells under basal conditions or upon treatment with conditioned media derived from MRC-5 or WI38 cells.
  • Cells were treated with kinase inhibitors (1 ⁇ ) for 2 hours prior to HGF treatment.
  • FIG. 5 Bi-directional crosstalk between IGF-1R/IR and either EGFR or MET.
  • FIG. 5 Knockdown of MET is associated with increased sensitivity to erlotinib, OSl-906, and the combination of erlotinib and OSl-906.
  • B Effect of varying concentrations of erlotinib (top panel) or OSl-906 (bottom panel) on induction of caspase 3/7 activity for EV control or MET KD GEO cells.
  • FIG. Cartoon outlining hypotheses for crosstalk between the IGF, EGF, and HGF axes.
  • FIG. 7 Summary of 35 tumor cell lines, highlighting EMT status as epithelial (E) or mesenchymal (M), erlotinib and OSl-906 sensitivity (EC50, uM), and level of phosphorylation of EGFR, IR, IGF-1R, and MET. Phosphorylation is highlighted when detected for a given tumor cell line. Also shown is the mutation status for KRAS, BRAF, PIK3CA, and PTEN as described by the Sanger Institute.
  • FIG. 8 Neither FGF1/2 or PDGFa treatment is sufficient to rescue activation of AKT pathway signaling in GEO tumor cells treated with OSl-906 or erlotinib. Effect of OSl-906, erlotinib, or the combination of OSl-906 and erlotinib on pAKT-S473 and pPRAS40 in GEO cells cultured under basal growing conditions or treated with FGF1/2 or PDGFa for 5 minutes prior to harvesting and analysis of phospho-proteins .
  • FIG. 9 Treatment with OSl-906 results in enhanced phosphorylation of EGFR, ErbB3, and MET in GEO tumor cells. Effect of OSl-906 treatment on phosphorylation for a panel of 42 RTKs in GEO tumor cells. RTK phosphorylation was assessed using the RTK array (ARY001) (R&D Systems).
  • Figure 10 Knockdown of MET using shRNA in GEO tumor cells is associated with a 91% reduction in mRNA expression and loss of detectable MET phosphorylation.
  • cancer in an animal refers to the presence of cells possessing characteristics typical of cancer-causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features. Often, cancer cells will be in the form of a tumor, but such cells may exist alone within an animal, or may circulate in the blood stream as independent cells, such as leukemic cells.
  • Cell growth as used herein, for example in the context of "tumor cell growth”, unless otherwise indicated, is used as commonly used in oncology, where the term is principally associated with growth in cell numbers, which occurs by means of cell reproduction (i.e. proliferation) when the rate of the latter is greater than the rate of cell death (e.g. by apoptosis or necrosis), to produce an increase in the size of a population of cells, although a small component of that growth may in certain circumstances be due also to an increase in cell size or cytoplasmic volume of individual cells.
  • An agent that inhibits cell growth can thus do so by either inhibiting proliferation or stimulating cell death, or both, such that the equilibrium between these two opposing processes is altered.
  • Tumor growth or tumor metastases growth
  • oncology where the term is principally associated with an increased mass or volume of the tumor or tumor metastases, primarily as a result of tumor cell growth.
  • Abnormal cell growth refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition).
  • tumor cells tumor cells
  • mutated tyrosine kinase a mutated tyrosine kinase or over-expression of a receptor tyrosine kinase
  • benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs a tumor cells that proliferate by expressing a mutated tyrosine kinase or over-expression of a receptor tyrosine kinase
  • benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs (4) any tumors that proliferate by receptor tyrosine kinases; (5) any tumors that proliferate by aberrant serine/threonine kinase activation; and (6) benign and malignant cells of other proliferative diseases in which aberrant serine/threonine kinase activation occurs.
  • treating means to give medical aid to counteract a disease or condition.
  • a method of treating or its equivalent, when applied to cancer refers to a procedure or course of action that is designed to reduce or eliminate the number of cancer cells in a patient, or to alleviate the symptoms of a cancer.
  • a method of treating does not necessarily mean that the cancer cells or other disorder will, in fact, be eliminated, that the number of cells or disorder will, in fact, be reduced, or that the symptoms of a cancer or other disorder will, in fact, be alleviated.
  • a method of treating cancer will be performed even with a low likelihood of success, but which, given the medical history and estimated survival expectancy of a patient, is nevertheless deemed an overall beneficial course of action.
  • terapéuticaally effective agent means a composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • terapéuticaally effective amount or “effective amount” means the amount of the subject compound or combination that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • responsive'Or “responsiveness” when used herein in referring to a patient's reaction to administration of an IGF-IR kinase inhibitor refers to a response that is positive or effective, from which the patient is likely to benefit.
  • method for manufacturing a medicament or "use of for
  • manufacturing a medicament relates to the manufacturing of a medicament for use in the indication as specified herein, and in particular for use in tumors, tumor metastases, or cancer in general.
  • antibody molecule refers to a protein of the immunoglobulin (Ig) superfamily that binds noncovalently to certain substances (e.g. antigens and immunogens) to form an antibody - antigen complex, including but not limited to antibodies produced by hybridoma cell lines, by immunization to elicit a polyclonal antibody response, by chemical synthesis, and by recombinant host cells that have been transformed with an expression vector that encodes the antibody.
  • the immunoglobulin antibodies are classified as IgA, IgD, IgE, IgG, and IgM and members of each class are said to have the same isotype.
  • Human IgA and IgG isotypes are further subdivided into subtypes IgAi, and IgA 2 , and IgGi, IgG 2 , IgG 3 , and IgG 4 .
  • Mice have generally the same isotypes as humans, but the IgG isotype is subdivided into IgGi, IgG 2a réelle IgG 2 b, and IgG 3 subtypes.
  • antibody molecule as used herein includes within its scope (a) any of the various classes or sub-classes of immunoglobulin, e.g., IgG, IgM, IgE derived from any of the animals conventionally used and (b) polyclonal and monoclonal antibodies, such as murine, chimeric, or humanized antibodies.
  • Antibody molecules have regions of amino acid sequences that can act as an antigenic determinant, e.g. the Fc region, the kappa light chain, the lambda light chain, the hinge region, etc.
  • An antibody that is generated against a selected region is designated anti-[region], e.g.
  • antibody molecule also covers any polypeptide or protein having a binding domain that is, or is homologous to, an antibody binding domain, including, without limitation, single-chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker that allows the two domains to associate to form an antigen binding site (Bird et al., Science 242, 423 (1988) and Huston et al, Proc. Natl. Acad. Sci. USA 85, 5879 (1988)). These can be derived from natural sources, or they may be partly or wholly synthetically produced.
  • scFv single-chain Fv molecules
  • antibody fragments refers to fragments of antibody molecules that retain the principal selective binding characteristics of the whole antibody molecule. Particular fragments are well-known in the art, for example, Fab, Fab', and F(ab') 2 , which are obtained by digestion with various proteases and which lack the Fc fragment of an intact antibody or the so-called "half-molecule" fragments obtained by reductive cleavage of the disulfide bonds connecting the heavy chain components in the intact antibody.
  • Such fragments also include isolated fragments consisting of the light-chain-variable region, "Fv” fragments consisting of the variable regions of the heavy and light chains, and recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker.
  • Other examples of binding fragments include (i) the Fd fragment, consisting of the VH and CHI domains; (ii) the dAb fragment (Ward, et al, Nature 341, 544 (1989)), which consists of a VH domain; (iii) isolated CDR regions; and (iv) single-chain Fv molecules (scFv) described above.
  • arbitrary fragments can be made using
  • IGF-1R kinase inhibitors may be small molecule IGF- 1R kinase inhibitors, anti-IGF-lR antibodies, or agents that antagonize activation of IGF-1R, such as IGF binding proteins (e.g.
  • inhibitors of MET kinase may be small molecule MET kinase inhibitors, anti-MET antibodies, or agents that antagonize activation of MET receptor, such as HGF binding proteins (e.g. an anti-HGF antibody).
  • Preferred small molecule IGF-1R kinase inhibitors for use in these combinations are a new class of relatively specific, orally-available, small-molecule compounds as described, for example, in US Published Patent Application US 2006/0235031, such as the compound OSI-906, a molecule that also has inhibitory activity on IR kinase.
  • Another preferred molecule is a small molecule kinase inhibitor that inhibitors both IGF-IR kinase and MET kinase, and preferably also IR kinase, e.g. BMS754807 (see Carboni, J.M. et al. (2009) Mol Cancer Ther 8(12):3341-3349, including Supplemental Figures and Tables).
  • BMS754807 see Carboni, J.M. et al. (2009) Mol Cancer Ther 8(12):3341-3349, including Supplemental Figures and Tables.
  • the latter compound demonstrates that it is possible to design kinase inhibitors that have dual specificity for IGF-IR kinase and MET kinase.
  • an IGF-IR kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • an MET kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • co-administration of these agents can be effective for treatment of patients with advanced cancers such as NSCL, pancreatic, head and neck, colon, ovarian and breast cancers.
  • This combination was found to produce a synergistic effect in inhibiting the growth of tumor cells, apparently at least in part by the MET kinase inhibitor increasing the potency of the IGF-IR kinase inhibitor to inhibit tumor cell growth.
  • the present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of a MET kinase inhibitor (e.g. a small molecule MET kinase inhibitor or an anti-MET antibody) and an IGF-IR kinase inhibitor (e.g. a small molecule IGF-IR kinase inhibitor such as that of Formula (I) described herein (e.g. OSI-906); or an anti-IGF-lR antibody).
  • a MET kinase inhibitor e.g. a small molecule MET kinase inhibitor or an anti-MET antibody
  • an IGF-IR kinase inhibitor e.g. a small molecule IGF-IR kinase inhibitor such as that of Formula (I) described herein (e.g. OSI-906); or an anti-IGF-lR antibody.
  • the present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of one or more IGF binding proteins (e.g. IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti-IGF-2 antibody) and a MET kinase inhibitor.
  • IGF binding proteins e.g. IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti-IGF-2 antibody
  • MET kinase inhibitor e.g. IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti-IGF-2 antibody
  • the patient is a human that is in need of treatment for cancer.
  • the combination of two inhibitors are coadministered to the patient in the same formulation; are co -administered to the patient in different formulations; are co -administered to the patient by the same route; or are co-administered to the patient by different routes.
  • one or more other anti-cancer agents can additionally be administered to said patient.
  • an “antibody” in the methods, compositions or kits of this invention optionally includes “antibody molecules”, “antibody fragments”, or mixtures of such antibody molecules or fragments.
  • an “anti-IGF-lR antibody” includes any anti-IGF-lR antibody or antibody fragment that can partially or completely block IGF-1R activation by its natural ligands IGF-1 and IGF-2.
  • Non-limiting examples of antibody-based IGF- 1R kinase inhibitors include those described in Larsson, O. et al (2005) Brit. J. Cancer 92:2097-2101 and (2004), Y.H. and Yee, D. (2005) Clin. Cancer Res.
  • IGF-1R neutralizing antibodies that are in pre-clinical (e.g. hlOH5, Genentech) or clinical (e.g. CP-751,871, Pfizer; IMC-A12, Imclone; MK0646, Merck; AMG479, Amgen; SCH717454, Schering; R1507, Roche; AVE-1642, Aventis; and BIIB022, Biogen) development (see Rodon et al. (2008) Mol. Cancer Ther. 7(9): 2575- 2588).
  • the IGF-1R kinase inhibitor of this invention can be a monoclonal antibody, or an antibody or antibody fragment having the binding specificity thereof.
  • the anti-IGF-lR antibody is a humanized monoclonal antibody.
  • an an "IGF binding protein” includes any protein that binds to IGF-1 and/or IGF-2 and can partially or completely block IGF-1R activation by these ligands.
  • IGF binding proteins include insulin-like growth factor binding proteins (Rajaram S, et al. (1998) "Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions.” Endocr. Rev. 18(6): 801-31; Ferry RJ, et al. (1999) "Insulin-like growth factor binding proteins: new proteins, new functions.” Horm. Res.
  • IGFBP3 insulin-like growth factor binding protein 3; GenelD: 3486; GenBank Database Accession numbers of precursor protein iso forms a and b, NP 001013416, NP 000589), an IGF-binding fragment thereof, or a protein comprising such a fragment, including recombinant fusion proteins comprising an IGF-binding fragment of IGFBP3; an IGFBP3 protein comprising amino acid residues 2-265 of SEQ ID No. 1 herein below; a recombinant human IGFBP3 (rhIGFBP3) being developed by Insmed Inc.
  • IGFBP-3 fusion protein e.g. see US Patent 7,192,738,
  • IGFBP1 insulin-like growth factor binding protein 1; GenelD: 3484; GenBank Database Accession number of precursor protein
  • IGFBP2 insulin-like growth factor binding protein 2; GenelD: 3485; GenBank Database Accession number of precursor protein, NP 000588)
  • IGFBP4 insulin-like growth factor binding protein 4; GenelD: 3487; GenBank Database Accession number of precursor protein, NP 001543
  • IGFBP5 insulin-like growth factor binding protein 5; GenelD: 3488; GenBank Database Accession number of precursor protein, NP 000590
  • IGFBP6 insulin-like growth factor binding protein 6; GenelD: 3489; GenBank Database Accession number of precursor protein,
  • IGFBP7 insulin-like growth factor binding protein 7; GenelD: 3490; GenBank Database Accession number of precursor protein, NP_001544
  • an anti- IGF-1 or anti-IGF-2 antibody or antibody fragment that can partially or completely block IGF-1R activation by IGF-1 and/or IGF-2 (e.g. MEDI-573; or see Miyamoto, S. et al. (2005) Clinical Cancer Research 11 :3494-3502; anti-IGF2 antibodies in development by Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan); and soluble extracellular domains of IGF-1 R that can bind to and partially or completely block IGF-1R activation by IGF-1 and/or IGF-2.
  • the "IGF binding protein” may be repaced by an "IGF binding aptamer” that can partially or completely block IGF-1R activation by IGF-1 and/or IGF-2.
  • IGF binding proteins that may be used in the instant invention include those described in: U.S. Pat. No. 6,417,330, WO 99/63086, and U.S. application No. 2002/0072589, that disclose IGFBP-3 variants modified to be resistant to hydrolysis, and variant IGFBP-3s where the nuclear localization signal (NLS) in native IGFBP-3 is altered; McCaig et al, Br. J. Cancer, 86: 1963 1969 (2002), and Perks et al, Biochim. Biophys. Res. Comm.
  • IGF binding polypeptides consisting of the amino acids 39-91 of IGFBP-1, the amino acids 55-107 of IGFBP-2, the amino acids 47-99 of IGFBP-3, the amino acids 39-91 of IGFBP4, the amino acids 40-92 of IGFBP-5, or the amino acids 40-92 of IGFBP-6, fragments thereof, and IGFBP mutants with enhanced binding affinity for IGF-I and/or IGF-II;
  • WO 00/23469 that discloses IGFBP fragments that account for IGF-IGFBP binding, and provides an isolated IGF binding domain of an IGFBP or modifications thereof, which binds IGF with at least about the same binding affinity as the full-length IGFBP, including isolated IGF binding domains of IGFBP 1, IGFBP3, IGFBP4, IGFBP5, and IGFBP
  • NCBI GenelD numbers listed herein are unique identifiers of the gene from the NCBI Entrez Gene database record (National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine, 8600 Rockville Pike, Building 38 A, Bethesda, MD 20894; Internet address www.ncbi.nlm.nih.gov).
  • IGF binding proteins expressed by genes thus identified represent proteins that may be used in the methods of this invention, and the sequences of these proteins, including different isoforms, as disclosed in NCBI database records are herein incorporated by reference.
  • small molecule inhibitor refers to a low molecular weight (i.e. less than 5000 Daltons; preferably less than 1000, and more preferably between 300 and 700 Daltons) organic compound that inhibits a target protein, e.g. IGF-1R kinase or MET kinase, by for example binding to the kinase domain of the enzyme.
  • target protein e.g. IGF-1R kinase or MET kinase
  • examples of such compounds include IGF-1R kinase inhibitors of Formula (I) as described herein.
  • the IGF-1R kinase inhibitor of Formula (I) can be any IGF-1R kinase inhibitor compound encompassed by Formula (I) that inhibits IGF-1R kinase upon administration to a patient.
  • IGF-1R kinase inhibitor compounds encompassed by Formula (I) that inhibits IGF-1R kinase upon administration to a patient.
  • OSI-906 cz ' 5-3-[8-amino-l -(2-phenyl-quinolin-7-yl)-imidazo[ 1 ,5-a]pyrazin-3-yl]- 1 - methyl-cyclobutanol
  • IGF-1R kinase inhibitor of Formula (I) is represented by the formula:
  • Xi, and X 2 are each independently N or C-(E 1 ) aa ;
  • X 5 is N, C-(E 1 ) aa , or
  • X 3 , X 4 , X 6 , and X 7 are each independently N or C; wherein at least one of X 3 , X 4 , X 5 ,
  • X 6 , and X 7 is independently N or N-(E 1 ) aa ;
  • Xii, X 12 , Xi3, Xi4, Xi5, and X 16 are each independently N, C-(E u )bb, or N + -0 " ;
  • R 1 is absent, C 0-10 alkyl, cycloC 3 _ioalkyl, bicycloC 5 _ioalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterobicycloCs_ioalkyl, spiroalkyl, or heterospiroalkyl, any of which is optionally substituted by one or more independent G 11 substituents;
  • E 1 , E 11 , G 1 , and G 41 are each independently halo, -CF 3 , -OCF 3 , -OR 2 , -NR 2 R 3 (R 2a ) j i,
  • heterocyclyl-C 2 -ioalkenyl or heterocyclyl-C 2 -ioalkynyl, any of which is optionally
  • E 1 , E 11 , or G 1 optionally is -(W ⁇ -CY ⁇ -R 4 ;
  • Ci_i 0 alkylidene C 0 _i 0 alkyl, C 2 -i 0 alkenyl, C 2 -i 0 alkynyl, Ci_i 0 alkoxyCi_ l oalkyl, Ci_ioalkoxyC 2 -ioalkenyl, Ci_ioalkoxyC 2 -ioalkynyl, Ci_ioalkylthioCi_ioalkyl, Ci_ ioalkylthioC 2 -ioalkenyl, Ci_ioalkylthioC 2 -ioalkynyl, cycloC 3 -galkyl, cycloC 3 -salkeny
  • R 333al are each independently Co_ioalkyl, C 2 _ioalkenyl, C 2 _ioalkynyl, Ci_ioalkoxyCi_ l oalkyl, Ci_ioalkoxyC 2 _ioalkenyl, Ci_ioalkoxyC 2 _ioalkynyl, Ci_ioalkylthioCi_ioalkyl, Ci_ ioalkylthioC 2 _ioalkenyl, Ci_ioalkylthioC 2 _ioalkynyl, cycloC 3 _galkyl, cycloC 3 _galkenyl, cycloC 3 _galkylCi_ioalkyl, cycloC 3 _galkenylCi_ioalkyl, cycloC 3 _galkenylCi_ioalkyl, cycloC 3 _galkylC 2 _ioalkeny
  • R 222 and R 333 , or R 2221 and R 3331 are optionally taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted by one or more independent G 1111 substituents and wherein said ring optionally includes one or more heteroatoms other than the nitrogen to which R 2 and R 3 , or R 222 and R 333 , or R 2221 and R 3331 are attached;
  • W 1 and Y 1 are each independently -0-, -NR 7 -, -S(0) j7 - -CR 5 R 6 -, -N(C(0)OR 7 )-, -N(C(0)R 7 )-, -N(S0 2 R 7 )-, -CH 2 O-, -CH 2 S- -CH 2 N(R 7 )-, -CH(NR 7 )-,
  • R 5 with R 6 are optionally taken together with the carbon atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted with one or more independent R 69 substituents and wherein said ring optionally includes one or more heteroatoms;
  • R 7 , R 7a , and R 8 are each independently acyl, Co-ioalkyl, C 2 _ioalkenyl, aryl, heteroaryl, heterocyclyl or cycloC 3 _ioalkyl, any of which is optionally substituted by one or more independent G 111 substituents;
  • R 4 is Co-ioalkyl, C 2 _ioalkenyl, C 2 _ioalkynyl, aryl, heteroaryl, cycloC 3 _ioalkyl,
  • heterocyclyl cycloC 3 _ 8 alkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G 41 substituents;
  • R 69 is aryl-Co-ioalkyl, aryl-C 2 _ioalkenyl, aryl-C 2 _ioalkynyl, hetaryl-Co-ioalkyl, hetaryl-C 2 _ioalkenyl, hetaryl-C 2 _ioalkynyl, mono(Ci_ 6 alkyl)aminoCi_ 6 alkyl, di(Ci_ 6 alkyl)aminoCi_ 6 alkyl, mono(aryl)aminoCi_ 6 alkyl, di(aryl)aminoCi_ 6 alkyl, or
  • Ci_ioalkyl C 2 _ioalkenyl, C 2 _ioalkynyl, haloCi_ l oalkyl, haloC 2 _ioalkenyl, haloC 2 _ioalkynyl, -COOH, Ci_ 4 alkoxycarbonyl,
  • R 78 and R 88 are optionally taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, Ci_i 0 alkoxy, -S0 2 NR 778 R 888 , or -NR 778 R 888 substituents, and wherein said ring optionally includes one or more heteroatoms other than the nitrogen to which R 78 and R 88 are attached;
  • R 77 , R 78 , R 87 , R 88 , R 778 , and R 888 are each independently C 0 -i 0 alkyl, C 2 _i 0 alkenyl, C 2 _ l oalkynyl, Ci_ioalkoxyCi_ioalkyl, Ci_ioalkoxyC 2 _ioalkenyl, Ci_ioalkoxyC 2 _ioalkynyl, Ci_ ioalkylthioCi_ioalkyl, Ci_ioalkylthioC 2 _ioalkenyl, Ci_ioalkylthioC 2 _ioalkynyl, cycloC 3 _ 8 alkyl, cycloC 3 _ 8 alkenyl, cycloC 3 _ 8 alkylCi_ioalkyl, cycloC 3 - 8 alkenylCi_ioalkyl, cycloC 3
  • Ci_ioalkoxycarbonyl Ci_ioalkoxycarbonylCi_ioalkyl, monoCi_ 6 alkylaminocarbonyl, diC i_ 6 alkylaminocarbonyl, mono(aryl)aminocarbonyl, di(aryl)aminocarbonyl, or Ci_ioalkyl(aryl)aminocarbonyl, any of which is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, Ci_ioalkoxy, -S0 2 N(Co- 4 alkyl)(C 0 - 4 alkyl), or -N(C 0 - 4 alkyl)(C 0 - 4 alkyl) substituents;
  • R 77 , R 78 , R 87 , R 88 , R 778 , and R 888 are each independently aryl-C 0 -i 0 alkyl, aryl-C 2 _ l oalkenyl, aryl-C 2 _ioalkynyl, hetaryl-Co-ioalkyl, hetaryl-C 2 _ioalkenyl, hetaryl-C 2 _ l oalkynyl, mono(C i_ 6 alkyl)aminoC i_ 6 alkyl, di(C i_ 6 alkyl)aminoC i_ 6 alkyl,
  • n, m, j l, j la, j2a, j4, j4a, j5a, j7, andj8 are each independently 0, 1, or 2; and aa and bb are each independently 0 or 1.
  • IGF-IR kinase inhibitor compounds of Formula (I), such as OSI-906 (a.k.a. linsitinib), have a number of important advantages over other compounds that inhibit the IGF-IR signaling pathway. These include: (a) They are small molecule inhibitors and therefore, should be easier to dose in combination with other inhibitors (e.g.
  • BMS754807, BMS-536924 (both Bristol-Myers Squibb) inhibit both IGF-IR and IR in addition to a number of other kinases and are therefore less selective that IGF-IR kinase inhibitor compounds of Formula (I). This may contribute to the enhanced toxicity of these agents compared with IGF-IR kinase inhibitor compounds of Formula (I) (e.g. OSI-906).
  • the IGF-IR kinase inhibitor may be an IGF-IR kinase inhibitor as described in the following publications: Buck, E. and Mulvihill, M. (2011) Expert Opin. Investig. Drugs 20(4):605-621, and Rodon et al. (2008) Mol. Cancer Ther. 7(9): 2575-2588), that both describe IGF-IR kinase inhibitors in development by pharmaceutical companies; International Patent Publication No. WO 05/037836, that describes imidazopyrazine IGF-IR kinase inhibitors, International Patent Publication Nos. WO 03/018021 and WO 03/018022, that describe pyrimidines for treating IGF-IR related disorders, International Patent Publication Nos. WO 02/102804 and WO
  • IGF-1R kinase inhibitors in development by Novartis (e.g. NVP-AEW541, Garcia-Echeverria, C. et al. (2004) Cancer Cell 5:231- 239; or NVP-ADW742, Mitsiades, C.S. et al.
  • IGF-IR kinase inhibitors that may be useful in alternative embodiments of any of the methods, compositions or kits of the invention described herein include, for example imidazopyrazine IGF-IR kinase inhibitors, quinazoline IGF-IR kinase inhibitors, pyrido-pyrimidine IGF-IR kinase inhibitors, pyrimido-pyrimidine IGF-IR kinase inhibitors, pyrrolo-pyrimidine IGF-IR kinase inhibitors, pyrazolo-pyrimidine IGF-IR kinase inhibitors, phenylamino-pyrimidine IGF-IR kinase inhibitors, oxindole IGF-IR kinase inhibitors, indolocarbazole IGF-IR kinase inhibitors, phthalazine IGF-IR kinase inhibitors, isoflavone IGF-IR kinase inhibitors
  • IGF-IR kinase inhibitors include inhibitors that act by binding directly to the intracellular domain of the receptor and inhibiting its kinase activity; inhibitors that act by occupying the ligand binding site or a portion thereof of the IGF-1 receptor, thereby making the receptor inaccessible to its natural ligand so that its normal biological activity is prevented or reduced; and inhibitors that act by inhibiting the dimerization of IGF-IR polypeptides, or interaction of IGF-IR polypeptide with other proteins, or enhance ubiquitination and endocytotic degradation of IGF-IR.
  • IGF-IR kinase inhibitor can also act by reducing the amount of IGF-1 available to activate IGF-IR, by for example antagonizing the binding of IGF-1 to its receptor, by reducing the level of IGF-1, or by promoting the association of IGF-1 with proteins other than IGF-IR such as IGF binding proteins (e.g. IGFBP3).
  • IGF-IR kinase inhibitors include but are not limited to low molecular weight inhibitors, aptamers, antibodies or antibody fragments, antisense constructs, small inhibitory RNAs (i.e. RNA interference by dsRNA; RNAi), and ribozymes.
  • the MET kinase inhibitor may be a small molecule MET kinase inhibitor, an anti-MET antibody or antibody fragment, an agent that antagonize activation of MET receptor, such as an HGF binding protein or anti-HGF antibody or antibody fragment, or any other MET kinase inhibitor or MET antagonist.
  • MET antagonists useful in this invention include polypeptides that specifically bind to MET, anti-MET antibodies, MET small molecule inhibitors, receptor molecules and derivatives which bind specifically to MET, and fusions proteins.
  • MET antagonists also include antagonistic variants of MET polypeptides, RNA aptamers and peptibodies against MET and HGF.
  • anti-HGF antibodies, anti-HGF polypeptides, MET receptor molecules and derivatives which bind specifically to HGF examples of each of these are described herein below.
  • Anti-MET antibodies that are useful in the methods of the invention include any antibody that binds with sufficient affinity and specificity to MET and can reduce or inhibit MET activity.
  • the antibody selected will normally have a sufficiently strong binding affinity for MET, for example, the antibody may bind human MET with a Kd value of between 100 nM-1 pM.
  • Antibody affinities may be determined by a surface plasmon resonance based assay (such as the BIAcore assay as described in PCT
  • the anti-MET antibody of the invention can be used as a therapeutic agent in targeting and interfering with diseases or conditions wherein MET/HGF activity is involved.
  • the antibody may be subjected to other biological activity assays, e.g., in order to evaluate its effectiveness as a therapeutic.
  • assays are known in the art and depend on the target antigen and intended use for the antibody.
  • Anti-MET antibodies are known in the art (see, e.g.
  • Anti-HGF antibodies are well known in the art. See, e.g., Kim K J, et al. Clin Cancer Res. (2006) 12(4): 1292-8; WO2007/115049; WO2009/002521;
  • HuL2G7 Takeda), AV-299 (a.k.a. SCH900105; Aveo/Merck) and AMG-102 (Amgen).
  • MET receptor molecules or fragments thereof that specifically bind to HGF can be used in the methods of the invention, e.g., to bind to and sequester the HGF protein, thereby preventing it from signaling.
  • the MET receptor molecule, or HGF binding fragment thereof is a soluble form.
  • a soluble form of the receptor exerts an inhibitory effect on the biological activity of the MET protein by binding to HGF, thereby preventing it from binding to its natural receptors present on the surface of target cells.
  • MET receptor fusion proteins examples of which are described below.
  • a soluble MET receptor protein or chimeric MET receptor proteins of the present invention includes MET receptor proteins which are not fixed to the surface of cells via a transmembrane domain.
  • soluble forms of the MET receptor including chimeric receptor proteins, while capable of binding to and inactivating HGF, do not comprise a transmembrane domain and thus generally do not become associated with the cell membrane of cells in which the molecule is expressed. See, e.g., Kong-Beltran, M et al Cancer Cell (2004) 6(1): 75-84.
  • HGF molecules or fragments thereof that specifically bind to MET and block or reduce activation of MET, thereby preventing it from signaling, can be used in the methods of the invention.
  • Aptamers are nucleic acid molecules that form tertiary structures that specifically bind to a target molecule, such as a HGF polypeptide.
  • a HGF aptamer is a pegylated modified
  • a peptibody is a peptide sequence linked to an amino acid sequence encoding a fragment or portion of an immunoglobulin molecule.
  • Polypeptides may be derived from randomized sequences selected by any method for specific binding, including but not limited to, phage display technology.
  • the selected polypeptide may be linked to an amino acid sequence encoding the Fc portion of an immunoglobulin.
  • Peptibodies that specifically bind to and antagonize HGF or MET are also useful in the methods of the invention.
  • MET kinase antagonists include small molecules such as compounds described in U.S. Pat. No. 5,792,783; U.S. Pat. No. 5,834,504; U.S. Pat. No. 5,880,141; U.S. Pat. No. 6,297,238; U.S. Pat. No. 6,599,902; U.S. Pat. No. 6,790,852; US 2003/0125370; US 2004/0242603; US 2004/0198750; US 2004/0110758; US 2005/0009845; US 2005/0009840; US 2005/0245547; US 2005/0148574; US 2005/0101650; US
  • MET kinase inhibitors include OSI-296 (OSI Pharmaceuticals), PHA-665752 ((2R)-l-[[5-[(Z)-[5-[[(2,6- Dichlorophenyl)methyl] sulfonyl]-l,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4- dimethyl- lH-pyrrol-3-yl]carbonyl]-2-(l -pyrrolidinylmethyl)pyrrolidine; Pharmacia), a small molecule, ATP-competitive, active-site inhibitor of the catalytic activity of MET (Ma et al (2005) Clin. Cancer Res. 11 :2312-2319; Christensen et al (2003) Cancer Res. 63:7345-7355), MP470 (SuperGen), XL184 (Exelixis), E-7050 (Eisai), GSK
  • MetMAb (a.k.a. One-armed 5D5, OA5D5 or Onartuzumab; a humanized, monovalent, antagonistic anti- MET antibody; Genentech), and AMG102 (a fully human IgG2 monoclonal antibody; Amgen).
  • the MET kinase inhibitor and IGF-1R kinase inhibitor of this invention may also be activities that reside in the same molecule, and thus one molecule provides the combined inhibition of MET and IGF-1R signaling pathways. Furthermore, in embodiments with two molecules, the MET kinase inhibitor of this invention may also possess IGF-1R kinase inhibitory activity, and/or the IGF-1R kinase inhibitor of this invention may also possess MET kinase inhibitory activity. Inhibitors with IGF-1R kinase inhibitory activity may also possess IR kinase inhibitory activity.
  • An example of a molecule that is MET kinase inhibitor and an IGF-1R kinase inhibitor is the compound BMS754807 (e.g. see Carboni, J.M. et al. (2009) Mol Cancer Ther
  • the present invention also provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment an amount of a MET kinase inhibitor and an amount of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)).
  • an IGF-1R kinase inhibitor of Formula (I) e.g. an IGF-1R kinase inhibitor of Formula (I)
  • one or more other anti-cancer agents can additionally be administered to said patient.
  • the present invention also provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment a therapeutically effete amount of a MET kinase inhibitor and a therapeutically effete amount amount of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)).
  • a therapeutically effete amount of a MET kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • one or more other anti-cancer agents can additionally be administered to said patient.
  • the present invention also provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment an amount of an MET kinase inhibitor and an amount of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)); wherein at least one of the amounts is administered as a subtherapeutic amount.
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • one or more other anti-cancer agents can additionally be administered to said patient.
  • the present invention also provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment an amount of one or more IGF binding proteins (e.g. IGFBP3; IGFBPl; an anti-IGF-1 antibody; an anti- IGF-2 antibody) and; and an amount of MET kinase inhibitor.
  • one or more other anti-cancer agents can additionally be administered to said patient.
  • the present invention also provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment a therapeutically effective amount of one or more IGF binding proteins (e.g. IGFBP3; IGFBPl; an anti- IGF-1 antibody; an anti-IGF-2 antibody) and a therapeutically effective amount of a MET kinase inhibitor.
  • one or more other anti-cancer agents can additionally be administered to said patient.
  • the present invention also provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment an amount of one or more IGF binding proteins (e.g.
  • IGFBP3 IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti- IGF-2 antibody
  • an amount of an MET kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • one or more other anti-cancer agents can additionally be administered to said patient.
  • the present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a synergistically effective therapeutic amount of a combination of an MET kinase inhibitor and an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)).
  • an IGF-1R kinase inhibitor of Formula (I) e.g. an IGF-1R kinase inhibitor of Formula (I)
  • one or more other anti-cancer agents can additionally be administered to said patient.
  • the present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a synergistically effective therapeutic amount of a combination of one or more IGF binding proteins (e.g. IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti- IGF-2 antibody) and a MET kinase inhibitor.
  • one or more other anti-cancer agents can additionally be administered to said patient.
  • the cells of the tumors or tumor metastases may be relatively insensitive or refractory to treatment with either of the anti-cancer agents or treatments used in the combination when used as a single agent/treatment.
  • the present invention also provides a pharmaceutical composition comprising an MET kinase inhibitor and an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)), in a pharmaceutically acceptable carrier.
  • the pharmaceutical composition can additionally comprise one or more other anticancer agents.
  • the present invention also provides a pharmaceutical composition comprising one or more IGF binding proteins (e.g. IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti-IGF-2 antibody) and a MET kinase inhibitor, in a pharmaceutically acceptable carrier.
  • the pharmaceutical composition can additionally comprise one or more other anti-cancer agents.
  • the present invention also provides a kit comprising one or more containers, comprising an MET kinase inhibitor and an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)).
  • the kit containers may further include a pharmaceutically acceptable carrier.
  • the kit may further include a sterile diluent, which is preferably stored in a separate additional container.
  • the kit further comprising a package insert comprising printed instructions directing the use of a combined treatment of an MET kinase inhibitor and an IGF-IR kinase inhibitor (e.g.
  • kits comprising additional anti-cancer agents, agents that enhances the effect of such agents, or other compounds that improve the efficacy or tolerability of the treatment.
  • the present invention also provides a kit comprising one or more containers, comprising one or more IGF binding proteins (e.g. IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti-IGF-2 antibody) and a MET kinase inhibitor.
  • the kit containers may further include a pharmaceutically acceptable carrier.
  • the kit may further include a sterile diluent, which is preferably stored in a separate additional container.
  • the kit further comprising a package insert comprising printed instructions directing the use of a combined treatment of one or more IGF binding proteins (e.g.
  • the patient may be a patient in need of treatment for cancer, including, for example, NSCL, pancreatic, head and neck, colon, ovarian or breast cancers.
  • This invention also provides a method for treating abnormal cell growth of cells in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an MET kinase inhibitor and an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)).
  • an IGF-IR kinase inhibitor of Formula (I) e.g. an IGF-IR kinase inhibitor of Formula (I)
  • This invention also provides a method for treating abnormal cell growth of cells in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of one or more IGF binding proteins (e.g. IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti-IGF-2 antibody) and a MET kinase inhibitor.
  • IGF binding proteins e.g. IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti-IGF-2 antibody
  • MET kinase inhibitor e.g. IGFBP3; IGFBP1; an anti-IGF-1 antibody; an anti-IGF-2 antibody
  • the MET kinase inhibitor is administered at the same time as the IGF-IR kinase inhibitor. In another embodiment of the methods of this invention, MET kinase inhibitor is administered prior to the IGF- IR kinase inhibitor. In another embodiment of the methods of this invention, the MET kinase inhibitor is administered after the IGF-IR kinase inhibitor. In another embodiment of the methods of this invention, the IGF-IR kinase inhibitor is pre- administered prior to administration of a combination of an IGF-IR kinase inhibitor and the MET kinase inhibitor .
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, and in addition, one or more other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds that enhance the effects of such agents.
  • additional other cytotoxic, chemotherapeutic or anti-cancer agents include, for example: alkylating agents or agents with an alkylating action, such as cyclophosphamide (CTX; e.g. CYTOXAN®), chlorambucil (CHL; e.g.
  • alkylating agents or agents with an alkylating action such as cyclophosphamide (CTX; e.g. CYTOXAN®), chlorambucil (CHL; e.g.
  • LEUKERAN® cisplatin
  • CiP cisplatin
  • PLATINOL® busulfan
  • MYLERAN® melphalan
  • BCNU carmustine
  • TEM triethylenemelamine
  • MTX methotrexate
  • VP 16 etoposide
  • VEPESID® 6-mercaptopurine (6MP), 6-thiocguanine (6TG), cytarabine (Ara-C), 5-fluorouracil (5-FU), capecitabine (e.g.XELODA®), dacarbazine (DTIC), and the like; antibiotics, such as actinomycin D, doxorubicin (DXR; e.g.
  • ADRIAMYCIN® daunorubicin (daunomycin), bleomycin, mithramycin and the like
  • alkaloids such as vinca alkaloids such as vincristine (VCR), vinblastine, and the like
  • antitumor agents such as paclitaxel (e.g. TAXOL®) and pactitaxel derivatives, the cytostatic agents, glucocorticoids such as dexamethasone (DEX; e.g.
  • arnifostine e.g. ETHYOL®
  • doxorubicin lipo e.g. DOXIL®
  • gemcitabine e.g. GEMZAR®
  • daunorubicin lipo e.g. DAUNOXOME®
  • procarbazine mitomycin, docetaxel (e.g.
  • TAXOTERE® aldesleukin, carboplatin, oxaliplatin, cladribine, camptothecin, CPT 11 (irinotecan), 10-hydroxy 7-ethyl-camptothecin (SN38), floxuridine, fludarabine, ifosfamide, idarubicin, mesna, interferon beta, interferon alpha, mitoxantrone, topotecan, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, plicamycin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, paz
  • LY293646 wortmannin, ZM336372, L-779,450, filgrastim, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibrit
  • Additional chemotherapeutic agents that may be added to the combinations or treatments of this invention include therapeutic antibodies such as alemtuzumab (Campath), cetuximab (ERBITUX ® , Imclone), panitumumab (VECTIBIX ® , Amgen), pertuzumab (OMNITARG , 2C4, Genentech), tositumomab (Bexxar, Corixia), and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARG ® , Wyeth).
  • therapeutic antibodies such as alemtuzumab (Campath), cetuximab (ERBITUX ® , Imclone), panitumumab (VECTIBIX ® , Amgen), pertuzumab (OMNITARG , 2C4, Genentech), tositumomab (Bexxar, Corixia), and the antibody drug conjugate, gemtuzumab ozogamicin
  • Additional humanized monoclonal antibodies with therapeutic potential as agents in combination with the compounds of the invention include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizum
  • interleukin-12 p40 protein The interleukin-12 p40 protein.
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)) and an MET kinase inhibitor, and in addition, one or more anti-hormonal agents.
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • MET kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • anti-hormonal agents include natural or synthetic organic or peptidic compounds that act to regulate or inhibit hormone action on tumors.
  • Antihormonal agents include, for example: steroid receptor antagonists, anti- estrogens such as tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, other aromatase inhibitors, 42-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (e.g. FARESTON ® ); anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above; agonists and/or antagonists of
  • glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH) and LHRH (leuteinizing hormone- releasing hormone); the LHRH agonist goserelin acetate, commercially available as ZOLADEX ® (AstraZeneca); the LHRH antagonist D-alaninamide N-acetyl-3-(2- naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N6-( 3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6- (1- methylethyl)-L-lysyl -L-proline (e.g ANTIDE ® , Ares-Serono); the LHR
  • cytotoxic and other anticancer agents described above in chemotherapeutic regimens is generally well characterized in the cancer therapy arts, and their use herein falls under the same considerations for monitoring tolerance and effectiveness and for controlling administration routes and dosages, with some adjustments.
  • the actual dosages of the cytotoxic agents may vary depending upon the patient's cultured cell response determined by using histoculture methods. Generally, the dosage will be reduced compared to the amount used in the absence of additional other agents.
  • Typical dosages of an effective cytotoxic agent can be in the ranges
  • the actual dosage will depend upon the judgment of the physician, the condition of the patient, and the effectiveness of the therapeutic method based on the in vitro responsiveness of the primary cultured malignant cells or histocultured tissue sample, or the responses observed in the appropriate animal models.
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)) and an MET kinase inhibitor, and in addition, one or more angio genesis inhibitors.
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • an MET kinase inhibitor e.g. angiogenesis inhibitor
  • Anti-angiogenic agents include, for example: VEGFR inhibitors, such as SU- 5416 and SU-6668 (Sugen Inc. of South San Francisco, Calif, USA), or as described in, for example International Application Nos. WO 99/24440, WO 99/62890, WO 95/21613, WO 99/61422, WO 98/50356, WO 99/10349, WO 97/32856, WO 97/22596, WO 98/54093, WO 98/02438, WO 99/16755, and WO 98/02437, and U.S. Patent Nos.
  • VEGF inhibitors such as IM862 (Cytran Inc. of Kirkland, Wash., USA); angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colo.) and Chiron (Emeryville, Calif); OSI-930 (OSI
  • VEGF antibodies to antibodies to VEGF
  • bevacizumab e.g. AVASTINTM, Genentech, South San Francisco, CA
  • integrin receptor antagonists and integrin antagonists such as to ⁇ ⁇ ⁇ 3, ⁇ ⁇ ⁇ 5 and ⁇ ⁇ ⁇ 6 integrins, and subtypes thereof, e.g. cilengitide (EMD 121974)
  • EMD 121974 cilengitide
  • anti-integrin antibodies such as for example ⁇ ⁇ ⁇ 3 specific humanized antibodies (e.g. VITAXIN®); factors such as IFN-alpha (U.S. Patent Nos.
  • angiostatin and plasminogen fragments e.g. kringle 1-4, kringle 5, kringle 1-3 (O'Reilly, M. S. et al. (1994) Cell 79:315-328; Cao et al. (1996) J. Biol. Chem. 271 : 29461-29467; Cao et al. (1997) J. Biol. Chem. 272:22924-22928);
  • thrombospondin TSP-1; Frazier, (1991) Curr. Opin. Cell Biol. 3:792); platelet factor 4 (PF4); plasminogen activator/urokinase inhibitors; urokinase receptor antagonists; heparinases; fumagillin analogs such as TNP-4701; suramin and suramin analogs; angiostatic steroids; bFGF antagonists; flk-1 and fit- 1 antagonists; anti-angiogenesis agents such as MMP-2 (matrix -metalloproteinase 2) inhibitors and MMP-9 (matrix -metalloproteinase 9) inhibitors.
  • MMP-2 matrix -metalloproteinase 2 inhibitors
  • MMP-9 matrix -metalloproteinase 9 inhibitors.
  • MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix - metalloproteinases (i.e. MMP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).
  • MMP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13 matrix - metalloproteinases
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)) and an MET kinase inhibitor, and in addition, one or more other tumor cell pro-apoptotic or apoptosis-stimulating agents.
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • MET kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • tumor cell pro-apoptotic or apoptosis-stimulating agents e.g. an IGF-1R kinase inhibitor of Formula (I)
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)) and an MET kinase inhibitor, and in addition, one or more other signal transduction inhibitors.
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • MET kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • Signal transduction inhibitors include, for example: erbB2 receptor inhibitors, such as organic molecules, or antibodies that bind to the erbB2 receptor, for example, trastuzumab (e.g. HERCEPTIN ® ); inhibitors of other protein tyrosine-kinases, e.g. imitinib (e.g.
  • GLEEVEC ® EGFR kinase inhibitors (see herein below); ras inhibitors; raf inhibitors; MEK inhibitors; mTOR inhibitors, including mTOR inhibitors that bind to and directly inhibits both mTORCl and mTORC2 kinases; mTOR inhibitors that are dual PI3K/mTOR kinase inhibitors, such as for example the compound PI- 103 as described in Fan, Q-W et al (2006) Cancer Cell 9:341-349 and Knight, Z.A. et al.
  • mTOR inhibitors that are dual inhibitors of mTOR kinase and one or more other PIKK (or PIK-related) kinase family members.
  • Such members include MEC1, TEL1, RAD3, MEI-41, DNA-PK, ATM, ATR, TRRAP, PI3K, and PI4K kinases; cyclin dependent kinase inhibitors; protein kinase C inhibitors; PI-3 kinase inhibitors; and PDK-1 inhibitors (see Dancey, J. and Sausville, E.A. (2003) Nature Rev. Drug Discovery 2:92-313, for a description of several examples of such inhibitors, and their use in clinical trials for the treatment of cancer).
  • a three agent combination will also be inhibiting IR signaling.
  • a four agent combination where each of the agents inhibits only one of the IGF-IR signaling, IR signaling, EGFR signaling, or MET receptor signaling may be just as effective as this three agent combination.
  • the two agents inhibiting IGF-IR signaling and IR signaling may for example be antibodies specific to each of the two receptor proteins.
  • a selective inhibitor of IR signaling may inhibit IR alone, IR-A alone, or both.
  • ErbB2 receptor inhibitors include, for example: ErbB2 receptor inhibitors, such as GW-282974 (Glaxo Wellcome pic), monoclonal antibodies such as AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Tex., USA) and 2B-1 (Chiron), and erbB2 inhibitors such as those described in International Publication Nos. WO 98/02434, WO 99/35146, WO 99/35132, WO 98/02437, WO 97/13760, and WO 95/19970, and U.S. Patent Nos. 5,587,458, 5,877,305, 6,465,449 and 6,541,481.
  • mTOR inhibitor that binds to and directly inhibits both mTORCl and mTORC2 kinases refers to any mTOR inhibitor that binds to and directly inhibits both mTORCl and mTORC2 kinases that is currently known in the art, or will be identified in the future, and includes any chemical entity that, upon administration to a patient, binds to and results in direct inhibition of both mTORCl and mTORC2 kinases in the patient.
  • Examples of mTOR inhibitors useful in the invention described herein include those disclosed and claimed in US Patent
  • EGFR kinase inhibitor refers to any EGFR kinase inhibitor that is currently known in the art or that will be identified in the future, and includes any chemical entity that, upon administration to a patient, results in inhibition of a biological activity associated with activation of the EGF receptor in the patient, including any of the downstream biological effects otherwise resulting from the binding to EGFR of its natural ligand.
  • Such EGFR kinase inhibitors include any agent that can block EGFR activation or any of the downstream biological effects of EGFR activation that are relevant to treating cancer in a patient.
  • Such an inhibitor can act by binding directly to the intracellular domain of the receptor and inhibiting its kinase activity.
  • such an inhibitor can act by occupying the ligand binding site or a portion thereof of the EGF receptor, thereby making the receptor inaccessible to its natural ligand so that its normal biological activity is prevented or reduced.
  • EGFR kinase inhibitors include but are not limited to small molecule inhibitors, antibodies or antibody fragments, peptide or RNA aptamers, antisense constructs, small inhibitory RNAs (i.e. RNA interference by dsRNA; RNAi), and ribozymes.
  • the EGFR kinase inhibitor is a small organic molecule or an antibody that binds specifically to the human EGFR.
  • EGFR kinase inhibitors include, for example quinazoline EGFR kinase inhibitors, pyrido-pyrimidine EGFR kinase inhibitors, pyrimido-pyrimidine EGFR kinase inhibitors, pyrrolo-pyrimidine EGFR kinase inhibitors, pyrazolo-pyrimidine EGFR kinase inhibitors, phenylamino-pyrimidine EGFR kinase inhibitors, oxindole EGFR kinase inhibitors, indolocarbazole EGFR kinase inhibitors, phthalazine EGFR kinase inhibitors, isoflavone EGFR kinase inhibitors, quinalone EGFR kinase inhibitors, and tyrphostin EGFR kinase inhibitors, such as those described in the following patent publications, and all pharmaceutically acceptable salts and solvates of said
  • Additional non-limiting examples of small molecule EGFR kinase inhibitors include any of the EGFR kinase inhibitors described in Traxler, P., 1998, Exp. Opin. Ther. Patents 8(12): 1599-1625.
  • small molecule EGFR kinase inhibitors that can be used according to the present invention include [6,7-bis(2-methoxyethoxy) -4- quinazolin-4-yl]-(3-ethynylphenyl) amine (also known as OSI-774, erlotinib, or TARCEVA ® (erlotinib HC1); OSI Pharmaceuticals/Genentech/ Roche) (U.S. Pat. No. 5,747,498; International Patent Publication No. WO 01/34574, and Moyer, J.D. et al. (1997) Cancer Res.
  • CI-1033 (formerly known as PD183805; Pfizer) (Sherwood et al, 1999, Proc. Am. Assoc. Cancer Res. 40:723); PD-158780 (Pfizer); AG-1478 (University of California); CGP-59326 (Novartis); PKI-166 (Novartis); EKB- 569 (Wyeth); GW-2016 (also known as GW-572016 or lapatinib ditosylate; GSK); and gefitinib (also known as ZD1839 or IRESSATM; Astrazeneca) (Woodburn et al, 1997, Proc. Am. Assoc. Cancer Res. 38:633).
  • a particularly preferred small molecule EGFR kinase inhibitor that can be used according to the present invention is [6,7-bis(2- methoxyethoxy)-4-quinazolin-4-yl]-(3-ethynylphenyl) amine (i.e. erlotinib), its hydrochloride salt (i.e. erlotinib HC1, TARCEVA ® ), or other salt forms (e.g. erlotinib mesylate).
  • EGFR kinase inhibitors also include, for example multi -kinase inhibitors that have activity on EGFR kinase, i.e. inhibitors that inhibit EGFR kinase and one or more additional kinases.
  • Examples of such compounds include the EGFR and HER2 inhibitor CI-1033 (formerly known as PD183805; Pfizer); the EGFR and HER2 inhibitor GW-2016 (also known as GW-572016 or lapatinib ditosylate; GSK); the EGFR and JAK 2/3 inhibitor AG490 (a tyrphostin); the EGFR and HER2 inhibitor ARRY-334543 (Array BioPharma); BIBW-2992, an irreversible dual EGFR/HER2 kinase inhibitor (Boehringer Ingelheim Corp.); the EGFR and HER2 inhibitor EKB- 569 (Wyeth); the VEGF-R2 and EGFR inhibitor ZD6474 (also known as ZACTIMATM; AstraZeneca Pharmaceuticals), and the EGFR and HER2 inhibitor BMS-599626 (Bristol-Myers Squibb).
  • Antibody-based EGFR kinase inhibitors include any anti-EGFR antibody or antibody fragment that can partially or completely block EGFR activation by its natural ligand.
  • Non-limiting examples of antibody-based EGFR kinase inhibitors include those described in Modjtahedi, H., et al, 1993, Br. J. Cancer 67:247-253; Teramoto, T., et al, 1996, Cancer 77:639-645; Goldstein et al, 1995, Clin. Cancer Res. 1 : 1311-1318;
  • the EGFR kinase inhibitor can be the monoclonal antibody Mab E7.6.3 (Yang, X.D. et al. (1999) Cancer Res. 59: 1236-43), or Mab C225 (ATCC Accession No. HB-8508), or an antibody or antibody fragment having the binding specificity thereof.
  • Suitable monoclonal antibody EGFR kinase inhibitors include, but are not limited to, IMC-C225 (also known as cetuximab or ERBITUXTM; Imclone Systems), ABX-EGF (Abgenix), EMD 72000 (Merck KgaA, Darmstadt), RH3 (York Medical Bioscience Inc.), and MDX-447 (Medarex/ Merck KgaA).
  • EGFR kinase inhibitors for use in the present invention can alternatively be peptide or RNA aptamers. Such aptamers can for example interact with the
  • EGFR extracellular or intracellular domains of EGFR to inhibit EGFR kinase activity in cells.
  • An aptamer that interacts with the extracellular domain is preferred as it would not be necessary for such an aptamer to cross the plasma membrane of the target cell.
  • An aptamer could also interact with the ligand for EGFR (e.g. EGF, TGF-a), such that its ability to activate EGFR is inhibited.
  • EGFR kinase inhibitors for use in the present invention can alternatively be based on antisense oligonucleotide constructs.
  • Anti-sense oligonucleotides including anti-sense RNA molecules and anti-sense DNA molecules, would act to directly block the translation of EGFR mRNA by binding thereto and thus preventing protein translation or increasing mRNA degradation, thus decreasing the level of EGFR kinase protein, and thus activity, in a cell.
  • antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the mRNA transcript sequence encoding EGFR can be synthesized, e.g., by conventional phosphodiester techniques and administered by e.g., intravenous injection or infusion.
  • Methods for using antisense techniques for specifically inhibiting gene expression of genes whose sequence is known are well known in the art (e.g. see U.S. Patent Nos. 6,566,135; 6,566,131;
  • Small inhibitory RNAs can also function as EGFR kinase inhibitors for use in the present invention.
  • EGFR gene expression can be reduced by contacting the tumor, subject or cell with a small double stranded RNA (dsRNA), or a vector or construct causing the production of a small double stranded RNA, such that expression of EGFR is specifically inhibited (i.e. RNA interference or RNAi).
  • dsRNA small double stranded RNA
  • RNAi RNA interference
  • Methods for selecting an appropriate dsRNA or dsRNA-encoding vector are well known in the art for genes whose sequence is known (e.g. see Tuschi, T., et al. (1999) Genes Dev. 13(24):3191-3197; Elbashir, S.M.
  • Ribozymes can also function as EGFR kinase inhibitors for use in the present invention.
  • Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
  • the mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
  • Engineered hairpin or hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of EGFR mRNA sequences are thereby useful within the scope of the present invention.
  • ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which typically include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using, e.g., ribonuclease protection assays.
  • Both antisense oligonucleotides and ribozymes useful as EGFR kinase inhibitors can be prepared by known methods. These include techniques for chemical synthesis such as, e.g., by solid phase phosphoramadite chemical synthesis.
  • anti-sense RNA molecules can be generated by in vitro or in vivo transcription of DNA sequences encoding the RNA molecule.
  • DNA sequences can be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
  • suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
  • modifications to the oligonucleotides of the invention can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)) and an MET kinase inhibitor, and in addition, an anti-HER2 antibody or an immunotherapeutically active fragment thereof.
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • an anti-HER2 antibody or an immunotherapeutically active fragment thereof e.g. an anti-HER2 antibody
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)) and an MET kinase inhibitor, and in addition, one or more additional anti-pro liferative agents.
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • MET kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • additional anti-pro liferative agents e.g. an IGF-1R kinase inhibitor of Formula (I)
  • Additional antiproliferative agents include, for example: Inhibitors of the enzyme farnesyl protein transferase, PDGFR kinase inhibitors, including the compounds disclosed and claimed in U.S. patent Nos. 6,080,769, 6,194,438, 6,258,824, 6,586,447, 6,071,935, 6,495,564, 6,150,377, 6,596,735 and 6,479,513, and
  • PDGFR kinase inhibitor refers to any PDGFR kinase inhibitor that is currently known in the art or that will be identified in the future, and includes any chemical entity that, upon administration to a patient, results in inhibition of a biological activity associated with activation of the PDGF receptor in the patient, including any of the downstream biological effects otherwise resulting from the binding to PDGFR of its natural ligand.
  • PDGFR kinase inhibitors include any agent that can block PDGFR activation or any of the downstream biological effects of PDGFR activation that are relevant to treating cancer in a patient.
  • Such an inhibitor can act by binding directly to the intracellular domain of the receptor and inhibiting its kinase activity.
  • such an inhibitor can act by occupying the ligand binding site or a portion thereof of the PDGF receptor, thereby making the receptor inaccessible to its natural ligand so that its normal biological activity is prevented or reduced.
  • PDGFR kinase inhibitors include but are not limited to small molecule inhibitors, antibodies or antibody fragments, antisense constructs, small inhibitory RNAs (i.e. RNA interference by dsRNA; RNAi), and ribozymes.
  • PDGFR kinase inhibitors include anti-PDGF or anti- PDGFR aptamers, anti-PDGF or anti-PDGFR antibodies, or soluble PDGF receptor decoys that prevent binding of a PDGF to its cognate receptor.
  • the PDGFR kinase inhibitor is a small organic molecule or an antibody that binds specifically to the human PDGFR.
  • the ability of a compound or agent to serve as a PDGFR kinase inhibitor may be determined according to the methods known in art and, further, as set forth in, e.g., Dai et al., (2001) Genes & Dev. 15: 1913-25; Zippel, et al, (1989) Eur. J. Cell Biol. 50(2):428-34; and Zwiller, et al, (1991)
  • the invention includes PDGFR kinase inhibitors known in the art as well as those supported below and any and all equivalents that are within the scope of ordinary skill to create.
  • inhibitory antibodies directed against PDGF are known in the art, e.g., those described in U.S. Patent Nos. 5,976,534, 5,833,986, 5,817,310, 5,882,644, 5,662,904, 5,620,687, 5,468,468, and PCT WO 2003/025019, the contents of which are incorporated by reference in their entirety.
  • the invention includes N-phenyl-2-pyrimidine-amine derivatives that are PDGFR kinase inhibitors, such as those disclosed in U. S. Patent No. 5,521,184, as well as WO2003/013541, WO2003/078404, WO2003/099771, WO2003/015282, and WO2004/05282 which are hereby incorporated in their entirety by reference.
  • Small molecules that block the action of PDGF are known in the art, e.g., those described in U.S. Patent or Published Application Nos. 6,528,526 (PDGFR tyrosine kinase inhibitors), 6,524,347 (PDGFR tyrosine kinase inhibitors), 6,482,834 (PDGFR tyrosine kinase inhibitors), 6,472,391 (PDGFR tyrosine kinase inhibitors), 6,949,563, 6,696,434, 6,331,555, 6,251,905, 6,245,760, 6,207,667, 5,990,141, 5,700,822,
  • Proteins and polypeptides that block the action of PDGF are known in the art, e.g., those described in U.S. Patent Nos. 6,350,731 (PDGF peptide analogs), 5,952,304, the contents of which are incorporated by reference in their entirety.
  • Antisense oligonucleotides for the inhibition of PDGF are known in the art, e.g., those described in U.S. Patent Nos. 5,869,462, and 5,821,234, the contents of each of which are incorporated by reference in their entirety.
  • Aptamers also known as nucleic acid ligands
  • Aptamers for the inhibition of PDGF are known in the art, e.g., those described in, e.g., U.S. Patent Nos. 6,582,918, 6,229,002, 6,207,816, 5,668,264, 5,674,685, and 5,723,594, the contents of each of which are incorporated by reference in their entirety.
  • Other compounds for inhibiting PDGF known in the art include those described in U.S. Patent Nos.
  • tyrosine kinase inhibitors that are selective for tyrosine kinase receptor enzymes such as PDGFR are known (see, e.g., Spada and Myers ((1995) Exp. Opin. Ther. Patents, 5: 805) and Bridges ((1995) Exp. Opin. Ther. Patents, 5: 1245). Additionally Law and Lydon have summarized the anticancer potential of tyrosine kinase inhibitors ((1996) Emerging Drugs: The Prospect For Improved
  • U.S. Patent No. 6,528,526 describes substituted quinoxaline compounds that selectively inhibit platelet-derived growth factor-receptor (PDGFR) tyrosine kinase activity.
  • PDGFR platelet-derived growth factor-receptor
  • the known inhibitors of PDGFR tyrosine kinase activity includes quino line -based inhibitors reported by Maguire et al, ((1994) J. Med. Chem., 37: 2129), and by Dolle, et al, ((1994) J. Med. Chem., 37: 2627).
  • PDGFR kinase inhibitors include Imatinib (GLEEVEC ® ;
  • FGFR kinase inhibitor refers to any FGFR kinase inhibitor that is currently known in the art or that will be identified in the future, and includes any chemical entity that, upon administration to a patient, results in inhibition of a biological activity associated with activation of the FGF receptor in the patient, including any of the downstream biological effects otherwise resulting from the binding to FGFR of its natural ligand.
  • FGFR kinase inhibitors include any agent that can block FGFR activation or any of the downstream biological effects of FGFR activation that are relevant to treating cancer in a patient.
  • Such an inhibitor can act by binding directly to the intracellular domain of the receptor and inhibiting its kinase activity.
  • such an inhibitor can act by occupying the ligand binding site or a portion thereof of the FGF receptor, thereby making the receptor inaccessible to its natural ligand so that its normal biological activity is prevented or reduced.
  • FGFR kinase inhibitors include but are not limited to small molecule inhibitors, antibodies or antibody fragments, antisense constructs, small inhibitory RNAs (i.e. RNA interference by dsRNA; RNAi), and ribozymes.
  • FGFR kinase inhibitors include anti-FGF or anti-FGFR aptamers, anti- FGF or anti-FGFR antibodies, or soluble FGFR receptor decoys that prevent binding of a FGFR to its cognate receptor.
  • the FGFR kinase inhibitor is a small organic molecule or an antibody that binds specifically to the human FGFR.
  • Anti-FGFR antibodies include FR1-H7 (FGFR-1) and FR3-D11 (FGFR-3) (Imclone Systems, Inc.).
  • FGFR kinase inhibitors also include compounds that inhibit FGFR signal transduction by affecting the ability of heparan sulfate proteoglycans to modulate FGFR activity.
  • Heparan sulfate proteoglycans in the extracellular matrix can mediate the actions of FGF, e.g., protection from proteolysis, localization, storage, and internalization of growth factors (Faham, S. et al. (1998) Curr. Opin. Struct. Biol., 8:578-586), and may serve as low affinity FGF receptors that act to present FGF to its cognate FGFR, and/or to facilitate receptor oligomerization (Galzie, Z. et al. (1997) Biochem. Cell. Biol, 75:669-685).
  • the invention includes FGFR kinase inhibitors known in the art (e.g.
  • Examples of chemicals that may antagonize FGF action, and can thus be used as FGFR kinase inhibitors in the methods described herein, include suramin, structural analogs of suramin, pentosan polysulfate, scopolamine, angiostatin, sprouty, estradiol, carboxymethylbenzylamine dextran (CMDB7), suradista, insulin-like growth factor binding protein-3, ethanol, heparin (e.g., 6-O-desulfated heparin), small molecule heparin, protamine sulfate, cyclosporin A, or RNA ligands for bFGF.
  • CMDB7 carboxymethylbenzylamine dextran
  • pyrrolotriazine compounds 5,132,408 (Salk Institute; peptide FGF antagonists); and 5,945,422 (Warner-Lambert Company; 2-amino-substituted pyrido[2,3- d]pyrimidines);U.S. published Patent application Nos. 2005/0256154 (4-amino- thieno[3,2-c]pyridine-7-carboxylic acid amide compounds); and 2004/0204427
  • WO-2006112479 Kyowa Hakko Kogyo Co., Ltd.; azaheterocycles
  • WO-2006108482 Merck Patent GmbH; 9-(4-ureidophenyl)purine compounds
  • WO- 2006105844 Merck Patent GmbH; N-(3-pyrazolyl)-N'-4-(4-pyridinyloxy)phenyl)urea compounds
  • WO-2006094600 Merck Patent GmbH; tetrahydropyrroloquinoline derivatives
  • WO-2006050800 Merck Patent GmbH; ⁇ , ⁇ '-diarylurea derivatives
  • WO-2006050779 Merck Patent GmbH; N,N * -diarylurea derivatives
  • WO-2006042599 Merck Patent GmbH; phenylurea derivatives
  • WO-2005066211 Five Prime
  • WO-2005054246 Merck Patent GmbH; heterocyclyl amines
  • WO-2005028448 Merck Patent GmbH; 2-amino- 1 -benzyl- substituted benzimidazole derivatives
  • WO-2005011597 Irm Lie; substituted heterocyclic derivatives
  • WO-2004093812 Irm Llc/Scripps; 6-phenyl-7H-pyrrolo[2,3- d]pyrimidine derivatives
  • WO-2004046152 F. Hoffmann La Roche AG;
  • WO-2004041822 F. Hoffmann La Roche AG; pyrimido[4,5-d]pyrimidine derivatives); WO-2004018472 (F. Hoffmann La Roche AG; pyrimido[4,5-d]pyrimidine derivatives); WO-2004013145 (Bristol-Myers Squibb Company; pyrrolotriazine derivatives); WO-2004009784 (Bristol-Myers Squibb Company; pyrrolo[2,l-fJ[l,2,4]triazin-6-yl compounds); WO-2004009601 (Bristol- Myers Squibb Company; azaindole compounds); WO-2004001059 (Bristol-Myers Squibb Company; heterocyclic derivatives); WO-02102972 (Prochon Biotech
  • FGFR kinase inhibitors include RO-4396686 (Hoffmann-La Roche); CHIR-258 (Chiron; also known as TKI-258); PD 173074 (Pfizer); PD 166866 (Pfizer); ENK-834 and ENK-835 (both Enkam Pharmaceuticals A/S); and SU5402 (Pfizer).
  • FGFR kinase inhibitors that are also PDGFR kinase inhibitors that can be used according to the present invention include XL-999 (Exelixis); SU6668 (Pfizer); CHIR-258/TKI-258 (Chiron); R04383596 (Hoffmann-La Roche), and BIBF-1120 (Boehringer Ingelheim).
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)) and a MET kinase inhibitor, and in addition, a COX II (cyclooxygenase II ) inhibitor.
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • a MET kinase inhibitor e.g. MET kinase inhibitor
  • COX II cyclooxygenase II
  • useful COX-II inhibitors include alecoxib (e.g. CELEBREXTM) and valdecoxib (e.g. BEXTRATM).
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-1R kinase inhibitor (e.g. an IGF-1R kinase inhibitor of Formula (I)) and an MET kinase inhibitor, and in addition treatment with radiation or a radiopharmaceutical.
  • an IGF-1R kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • an MET kinase inhibitor e.g. an IGF-1R kinase inhibitor of Formula (I)
  • radiation or a radiopharmaceutical e.g. an IGF-1R kinase inhibitor of Formula (I)
  • the source of radiation can be either external or internal to the patient being treated.
  • the therapy is known as external beam radiation therapy (EBRT).
  • EBRT external beam radiation therapy
  • BT brachytherapy
  • Radioactive atoms for use in the context of this invention can be selected from the group including, but not limited to, radium, cesium-137, iridium-192, americium-241, gold-198, cobalt-57, copper-67, technetium- 99, iodine- 123 , iodine- 131, and indium- 111.
  • Radiation therapy is a standard treatment for controlling unresectable or inoperable tumors and/or tumor metastases. Improved results have been seen when radiation therapy has been combined with chemotherapy. Radiation therapy is based on the principle that high-dose radiation delivered to a target area will result in the death of reproductive cells in both tumor and normal tissues.
  • the radiation dosage regimen is generally defined in terms of radiation absorbed dose (Gy), time and fractionation, and must be carefully defined by the oncologist.
  • the amount of radiation a patient receives will depend on various considerations, but the two most important are the location of the tumor in relation to other critical structures or organs of the body, and the extent to which the tumor has spread.
  • a typical course of treatment for a patient undergoing radiation therapy will be a treatment schedule over a 1 to 6 week period, with a total dose of between 10 and 80 Gy administered to the patient in a single daily fraction of about 1.8 to 2.0 Gy, 5 days a week.
  • Parameters of adjuvant radiation therapies are, for example, contained in International Patent Publication WO 99/60023.
  • the present invention further provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)) and an MET kinase inhibitor, and in addition treatment with one or more agents capable of enhancing antitumor immune responses.
  • an IGF-IR kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • MET kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • agents capable of enhancing antitumor immune responses e.g. an IGF-IR kinase inhibitor of Formula (I)
  • CTLA4 cytotoxic lymphocyte antigen 4 antibodies
  • ipilimumab a.k.a. MDX-010, Bristol-Myers Squibb/Medarex
  • CTLA4 antibodies include those described in U.S. Patent No. 6,682,736.
  • the present invention further provides a method for reducing the side effects caused by the treatment of tumors or tumor metastases in a patient with an IGF-IR kinase inhibitor or a MET kinase inhibitor, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)) and an MET kinase inhibitor, in amounts that are effective to produce a superadditive or synergistic antitumor effect, and that are effective at inhibiting the growth of the tumor.
  • an IGF-IR kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • an MET kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • the present invention further provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment (i) an effective first amount of an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)); and (ii) an effective second amount of an agent that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor, wherein that agent is an MET kinase inhibitor.
  • an IGF-IR kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • an agent that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor, wherein that agent is an MET kinase inhibitor.
  • the present invention further provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment (i) a sub-therapeutic first amount of an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)); and (ii) a sub-therapeutic second amount of an agent that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor, wherein that agent is an MET kinase inhibitor.
  • an IGF-IR kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • a sub-therapeutic second amount of an agent that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor wherein that agent is an MET kinase inhibitor.
  • the present invention further provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment (i) an effective first amount of an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)); and (ii) a sub-therapeutic second amount of an agent that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor, wherein that agent is an MET kinase inhibitor.
  • an IGF-IR kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • a sub-therapeutic second amount of an agent that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor wherein that agent is an MET kinase inhibitor.
  • the present invention further provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment (i) a sub-therapeutic first amount of an IGF-IR kinase inhibitor (e.g. an IGF-IR kinase inhibitor of Formula (I)); and (ii) an effective second amount of an agent that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor, wherein that agent is an MET kinase inhibitor.
  • an IGF-IR kinase inhibitor e.g. an IGF-IR kinase inhibitor of Formula (I)
  • an agent that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor, wherein that agent is an MET kinase inhibitor.
  • the order of administration of the first and second amounts can be simultaneous or sequential, i.e. the agent that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor can be administered before the IGF-IR kinase inhibitor, after the IGF-IR kinase inhibitor, or at the same time as the IGF-IR kinase inhibitor.
  • an "effective amount" of an agent or therapy is as defined above.
  • a “sub -therapeutic amount” of an agent or therapy is an amount less than the effective amount for that agent or therapy, but when combined with an effective or sub-therapeutic amount of another agent or therapy can produce a result desired by the physician, due to, for example, synergy in the resulting efficacious effects, or reduced side effects.
  • the term "patient” preferably refers to a human in need of treatment with an anti-cancer agent for any purpose, and more preferably a human in need of such a treatment to treat cancer, or a precancerous condition or lesion.
  • the term "patient” can also refer to non-human animals, preferably mammals such as dogs, cats, horses, cows, pigs, sheep and non-human primates, among others, that are in need of treatment with an anti-cancer agent.
  • the patient is a human in need of treatment for cancer, including tumors and tumor metastases, or a precancerous condition or lesion, wherein the cancer is for example NSCL, pancreatic, head and neck, colon, ovarian or breast cancers, or Ewing's sarcoma.
  • Cancers that may be treated by any of the the methods described herein include lung cancer, NSCLC, SCLC (small-cell lung cancer), bronchioloalveolar cell lung cancer, bone cancer, skin cancer, cancer of the head and neck (e.g. SCCHN), cutaneous or intraocular melanoma, pancreatic cancer, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, colon or colorectal cancer, cancer of the small intestine, cancer of the endocrine system, colorectal cancer, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, Ewing's saccoma, ACC (Adrenocortical Carcinoma), HCC (hepatocellular carcinoma),
  • the precancerous condition or lesion includes, for example, the group consisting of oral leukoplakia, actinic keratosis (solar keratosis), precancerous polyps of the colon or rectum, gastric epithelial dysplasia, adenomatous dysplasia, hereditary nonpolyposis colon cancer syndrome (HNPCC), Barrett's esophagus, bladder dysplasia, and precancerous cervical conditions.
  • oral leukoplakia actinic keratosis (solar keratosis)
  • precancerous polyps of the colon or rectum gastric epithelial dysplasia
  • adenomatous dysplasia adenomatous dysplasia
  • HNPCC hereditary nonpolyposis colon cancer syndrome
  • Barrett's esophagus bladder dysplasia
  • precancerous cervical conditions for example, the group consisting of oral leukoplakia, actin
  • refractory as used herein is used to define a cancer for which treatment (e.g. chemotherapy drugs, biological agents, and/or radiation therapy) has proven to be ineffective.
  • a refractory cancer tumor may shrink, but not to the point where the treatment is determined to be effective. Typically however, the tumor stays the same size as it was before treatment (stable disease), or it grows (progressive disease).
  • the term can apply to any of the treatments or agents described herein, when used as single agents or combinations.
  • co-administration of and “coadministering" an IGF-IR kinase inhibitor e.g.
  • an IGF-IR kinase inhibitor of Formula (I)), and an MET kinase inhibitor refer to any administration of the two active agents, either separately or together, where the two active agents are administered as part of an appropriate dose regimen designed to obtain the benefit of the combination therapy.
  • the two active agents can be administered either as part of the same pharmaceutical composition or in separate pharmaceutical compositions.
  • the MET kinase inhibitor that sensitizes tumor cells to the effects of the small molecule IGF-IR kinase inhibitor e.g.
  • an IGF-IR kinase inhibitor of Formula (I)) can be administered prior to, at the same time as, or subsequent to administration of the IGF-IR kinase inhibitor, or in some combination thereof.
  • the IGF-IR kinase inhibitor is administered to the patient at repeated intervals, e.g., during a standard course of treatment
  • the MET kinase inhibitor that sensitizes tumor cells to the effects of the IGF-IR kinase inhibitor can be administered prior to, at the same time as, or subsequent to, each administration of the IGF-IR kinase inhibitor, or some combination thereof, or at different intervals in relation to therapy with the IGF-IR kinase inhibitor, or in a single dose prior to, at any time during, or subsequent to the course of treatment with the IGF-IR kinase inhibitor.
  • the IGF-IR kinase inhibitor and MET kinase inhibitor, or dual IGF-IR kinase/MET kinase inhibitor, will typically be administered to the patient in a dose regimen that provides for the most effective treatment of the cancer (from both efficacy and safety perspectives) for which the patient is being treated, as known in the art.
  • the IGF-IR kinase inhibitor and MET kinase inhibitor, or dual IGF-IR kinase/MET kinase inhibitor can be administered in any effective manner known in the art, such as by oral, topical, intravenous, intra-peritoneal, intramuscular, intra-articular, subcutaneous, intranasal, intra-ocular, vaginal, rectal, or intradermal routes, depending upon the type of cancer being treated, the type of the IGF-IR kinase inhibitor and MET kinase inhibitor, or dual IGF-IR kinase/MET kinase inhibitor, and the medical judgement of the prescribing physician as based, e.g., on the results of published clinical studies.
  • the amount and the timing of inhibitor administration will depend on the type (species, gender, age, weight, etc.) and condition of the patient being treated, the severity of the disease or condition being treated, and on the route of administration. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
  • the IGF-1R kinase inhibitor and MET kinase inhibitor, or dual IGF-1R kinase/MET kinase inhibitor can be administered with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, elixirs, syrups, and the like. Administration of such dosage forms can be carried out in single or multiple doses.
  • Carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
  • Oral pharmaceutical compositions can be suitably sweetened and/or flavored.
  • the IGF-1R kinase inhibitor and MET kinase inhibitor, or dual IGF-1R kinase/MET kinase inhibitor can be combined together with various pharmaceutically acceptable inert carriers in the form of sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, and the like. Administration of such dosage forms can be carried out in single or multiple doses.
  • Carriers include solid diluents or fillers, sterile aqueous media, and various non-toxic organic solvents, etc.
  • tablets containing one or both of the active agents are combined with any of various excipients such as, for example, micro -crystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine, along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinyl pyrrolidone, sucrose, gelatin and acacia.
  • excipients such as, for example, micro -crystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine
  • disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinyl pyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes.
  • Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • active agents may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like
  • solutions in either sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions comprising the active agent or a corresponding water-soluble salt thereof.
  • sterile aqueous solutions are preferably suitably buffered, and are also preferably rendered isotonic, e.g., with sufficient saline or glucose.
  • These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes.
  • the oily solutions are suitable for intra-articular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
  • the IGF-IR kinase inhibitor and/or MET kinase inhibitor, or dual IGF-IR kinase/MET kinase inhibitor by way of, for example, creams, lotions, jellies, gels, pastes, ointments, salves and the like, in accordance with standard pharmaceutical practice.
  • a topical formulation comprising the IGF-IR kinase inhibitor and MET kinase inhibitor, or dual IGF-IR kinase/MET kinase inhibitor, in about 0.1% (w/v) to about 5% (w/v) concentration can be prepared.
  • the active agents can be administered separately or together to animals using any of the forms and by any of the routes described above.
  • the IGF-IR kinase inhibitor and/or MET kinase inhibitor, or dual IGF-IR kinase/MET kinase inhibitor is administered in the form of a capsule, bolus, tablet, liquid drench, by injection or as an implant.
  • the IGF-IR kinase inhibitor and MET kinase inhibitor, or dual IGF-IR kinase/MET kinase inhibitor can be administered with the animal feedstuff, and for this purpose a concentrated feed additive or premix may be prepared for a normal animal feed.
  • Such formulations are prepared in a conventional manner in accordance with standard veterinary practice.
  • the present invention also encompasses the use of a therapeutically effective amount of a combination of an IGF-IR kinase inhibitor and a MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, for the manufacture of a medicament for the treatment of tumors or tumor metastases in a patient in need thereof, wherein each inhibitor in the combination can be administered to the patient either simultaneously or sequentially.
  • the present invention also encompasses the use of a synergistically effective combination of an IGF-IR kinase inhibitor and a MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, for the manufacture of a medicament for the treatment of tumors or tumor metastases in a patient in need thereof, wherein each inhibitor in the combination can be administered to the patient either simultaneously or sequentially.
  • the present invention also encompasses the use of a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, for the manufacture of a medicament for the treatment of abnormal cell growth in a patient in need thereof, wherein each inhibitor in the combination can be administered to the patient either simultaneously or sequentially.
  • the present invention also encompasses the use of a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, in combination with another anti-cancer agent or agent that enhances the effect of such an agent for the manufacture of a medicament for the treatment of tumors or tumor metastases in a patient in need thereof, wherein each inhibitor or agent in the combination can be administered to the patient either simultaneously or sequentially.
  • the other anti-cancer agent or agent that enhances the effect of such an agent can be any of the agents listed herein that can be added to the IGF-IR kinase inhibitor and MET kinase inhibitor combination, or a dual IGF-IR kinase/MET kinase inhibitor, when treating patients.
  • the present invention further provides for any of the "methods of treatment” (or methods for reducing the side effects caused by treatment) described herein, a corresponding "method for manufacturing a medicament", for administration with an IGF-IR kinase inhibitor, and use with the same indications and under identical conditions or modalities described for the method of treatment, characterized in that a MET kinase inhibitor is used, and such that where any additional agents, inhibitors or conditions are specified in alternative embodiments of the method of treatment they are also included in the corresponding alternative embodiment for the method for manufacturing a medicament.
  • the present invention further provides for any of the "methods of treatment” (or methods for reducing the side effects caused by treatment) described herein, a corresponding "method for manufacturing a medicament" for use with the same indications and under identical conditions or modalities described for the method of treatment, characterized in that a combination an IGF-IR kinase inhibitor, and a MET kinase inhibitor, is used, such that where any additional agents, inhibitors or conditions are specified in alternative embodiments of the method of treatment they are also included in the corresponding alternative embodiment for the method for manufacturing a medicament.
  • the present invention further provides, for any of the methods, compositions or kits of the invention described herein that include, e.g. in a step or ingredient, the phrase "comprising" a combination of IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, a corresponding method, composition or kit in which that phrase is substituted with the phrase
  • the invention also encompasses a pharmaceutical composition that is comprised of a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, in combination with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier Preferably the composition is comprised of a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, (including pharmaceutically acceptable salts of each component thereof).
  • the invention encompasses a pharmaceutical composition for the treatment of disease, the use of which results in the inhibition of growth of neoplastic cells, benign or malignant tumors, or metastases, comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, (including pharmaceutically acceptable salts of each component thereof).
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • a compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases.
  • Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (cupric and cuprous), ferric, ferrous, lithium, magnesium, manganese (manganic and manganous), potassium, sodium, zinc and the like salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines.
  • Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, ⁇ ', ⁇ '-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylameine, tri
  • a compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic,
  • Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.
  • compositions of the present invention comprise a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF- IR kinase/MET kinase inhibitor, (including pharmaceutically acceptable salts of each component thereof) as active ingredients, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • Other therapeutic agents may include those cytotoxic, chemotherapeutic or anti-cancer agents, or agents which enhance the effects of such agents, as listed above.
  • compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • parenteral including subcutaneous, intramuscular, and intravenous
  • compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the compounds represented by the combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, (including pharmaceutically acceptable salts of each component thereof) of this invention can be combined as the active ingredient(s) in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous).
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion.
  • a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, (including pharmaceutically acceptable salts of each component thereof) may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy.
  • such methods include a step of bringing into association the active ingredients with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor or a dual IGF-IR kinase/MET kinase inhibitor, (including pharmaceutically acceptable salts of each component thereof).
  • a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, (including pharmaceutically acceptable salts of each component thereof) can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
  • Other therapeutically active compounds may include those cytotoxic, chemotherapeutic or anti-cancer agents, or agents which enhance the effects of such agents, as listed herein.
  • a pharmaceutical composition can comprise a combination of IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, in combination with another anticancer agent, wherein said anti-cancer agent is a member selected from the group consisting of alkylating drugs, antimetabolites, microtubule inhibitors, podophyllotoxins, antibiotics, nitrosoureas, hormone therapies, kinase inhibitors, activators of tumor cell apoptosis, and antiangiogenic agents.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
  • solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • compositions for oral dosage form any convenient means for preparing the compositions for oral dosage form.
  • oral liquid preparations such as suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
  • oral solid preparations such as powders, capsules and tablets.
  • tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably contains from about 0.05mg to about 5g of the active ingredient.
  • a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material that may vary from about 5 to about 95 percent of the total composition.
  • Unit dosage forms will generally contain between from about lmg to about 2g of the active ingredient, typically 25mg, 50mg, lOOmg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or lOOOmg.
  • compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
  • the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
  • the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
  • compositions of the present invention can be in a form suitable for topical sue such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a combination of an IGF-IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, (including pharmaceutically acceptable salts of each component thereof) of this invention, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds. [197] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
  • compositions containing a combination of an IGF- IR kinase inhibitor and an MET kinase inhibitor, or a dual IGF-IR kinase/MET kinase inhibitor, (including pharmaceutically acceptable salts of each component thereof) may also be prepared in powder or liquid concentrate form.
  • Dosage levels for the compounds of the combination of this invention will be approximately as described herein, or as described in the art for these compounds. It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
  • compositions or kits of this invention where an IGF-IR kinase inhibitor is used, an IGF-IR kinase inhibitor of Formula (I) as described herein may be used, and the IGF-IR kinase inhibitor may comprise any compound of Formula (I) as described in US Published Patent
  • compositions or kits of this invention where a MET kinase inhibitor is used, the MET kinase inhibitor may comprise any compound as described in WIPO Published Patent Application WO 2009/099982, WO 2011/109593, WO 2010 059771, WO 2011/143645 or WO 2009/100282.
  • IGF- IR kinase inhibitors useful in this invention include compounds represented by Formula (I) (see above), as described in US Published Patent Application US 2006/0235031, where their preparation is described in detail.
  • OSI-906 represents an IGF- IR kinase inhibitor according to Formula (I), with the formula czs-3-[8-amino-l -(2-phenyl-quinolin-7-yl)-imidazo[ 1 ,5-a]pyrazin-3-yl]- 1 - methyl-cyclobutanol.
  • OSI-906 and erlotinib were synthesized as previously described (31).
  • PHA a.k.a PHA-665752, i.e.
  • OSI-906 has the structure as follows:
  • Cell lines were obtained from the ATCC or other sources, banked after receipt, and propagated for fewer than 6 months before use. Cell viability was assayed at 72 hours after drug treatment using Cell Titer-Glo (Promega Corp., Madison, WI). Caspase 3/7 activity was assayed at 48 hours after drug treatment using Caspase-Glo (Promega Corp.)
  • Lysates for Western blotting were prepared as previously described (32). Antibodies included: IGF-1R and IR (Santa Cruz, 1 :200 dilution), phospho-p42/p44, phospho-Akt(S473) and phospho- Akt(T308), p-MET, and phospho-PRAS40 (Cell Signaling Technologies, 1 : 1000 dilution). Where indicated, 50ng/ml EGF or HGF ligands were added for 5 minutes prior to lysis. All other lysates were collected from cells growing under basal (10% FCS) growing conditions.
  • Taqman Assays Gene Expression Assay MET (Applied Biosystems, Foster City, CA) was conducted as described by the manufacturer using 50ng template.
  • GEO and MDA-1186 tumor cells grown to 20% confluence were treated with shRNA lentiviral particles (TRCN, Sigma) at a MOI of 2. After 48 hours cells were transferred to media containing 10 ⁇ g/ml puromycin for selection.
  • TRCN shRNA lentiviral particles
  • Receptors within the IGF, EGF, and HGF axes are coordinately expressed and activated
  • EGFR can be jointly activated with MET in select human tumors, and that compensatory MET activity can mediate acquired resistance to EGFR inhibitors (19, 20).
  • EGFR may also be co-activated with receptors within the IGF axis (IGF-1R and IR) in a subset of human tumor cell lines, where resistance to EGFR inhibitors including erlotinib is mediated by a compensatory increase in IGF-1R/IR activity.
  • IGF IGF-1R and IR
  • Tumor cell lines exhibited a range of sensitivities to the EGFR inhibitor erlotinib or the dual IGF-IR/IR inhibitor OSI-906 (33, 34). Phosphorylation levels for an RTK > 2-fold above the signal for IgG control were scored as detectable, Figure 7.
  • Phosphorylation array data for a representative subset of four tumor cell lines is shown in Figure IB. The majority of tumor cell lines (25/35) exhibited detectable levels of phospho-EGFR, which was positively correlated with sensitivity to erlotinib (Pearson correlation coefficient 0.4, p value 0.02), Table 1. 13/35 tumor cell lines showed detectable levels of phospho-IGF-lR/IR, Figure 7.
  • Sensitivity to OSI-906 was positively correlated with phosphorylation of IR and IGF-1R, and the correlation between phospho-IR and OSI-906 sensitivity was statistically significant (Pearson correlation coefficient 0.35, p value 0.04), Table 1. 13/35 tumor cell lines also exhibited detectable levels of phospho-MET. MET-dependence has been previously shown to be related to MET amplification (23, 24). Copy number analysis for MET is available for 22/35 tumor cell lines within the panel (CONAN, Sanger Wellcome Trust), and none showed high level amplification for the MET locus, including ten tumor cell lines with detectable phospho-MET, Figure 7.
  • EMT status has been described for 19 tumor cell lines within the panel (27-29). Consistent with previous reports, sensitivity to either erlotinib or OSI-906 was significantly positively correlated with an epithelial phenotype (Pearson correlation coefficients 0.60 and 0.67, respectively) (25, 27-29, 35). Phospho-EGFR, phospho-IR, and phospho-IGF-lR each trended towards being positively correlated with epithelial status. Interestingly, phospho-MET was also positively correlated with epithelial status, and this association was statistically significant (Pearson correlation coefficient 0.7, p value ⁇ 0.001), Table 1.
  • receptors within the EGF, IGF, and HGF axes are commonly co-expressed and phosphorylated in a subset of epithelial tumor cell lines (36). This supports the possibility for crosstalk between these three RTKs which could limit sensitivity to selective inhibition of an individual RTK or even to any paired combination of selective inhibitors.
  • Either EGF or HGF can promote desensitization to OSI-906
  • HGF-MET signaling may not be a primary determinant of cell proliferation for these tumor cell lines, HGF-MET signaling can contribute to acquired resistance to IGF-IR/IR inhibition, alone or in conjunction with EGFR inhibition.
  • OSI-906 synergizes with a MET kinase inhibitor to block cellular proliferation
  • PHA-665752 we evaluated the effect of combining OSI-906 with the MET kinase inhibitor, PHA-665752. While the anti-proliferative activities of either OSI-906 or erlotinib were significantly reduced by HGF treatment, PHA-665752 as a single agent had no effect on the proliferation of GEO tumor cells cultured under either basal or HGF- supplemented conditions. Therefore, while HGF-MET signaling may not be the primary determinant of cellular proliferation for these tumor cell lines, HGF-MET signaling can contribute to acquired resistance to either EGFR or IGF-1R/IR blockade, Figure 3A (top panel).
  • OSI-906 as a dual IGF-1R/IR inhibitor, exhibits greater anti-tumor activity compared with a selective IGF-1R antibody in tumor models such as GEO that co-express both IGF-1R and IR.
  • a selective IGF-1R antibody in tumor models such as GEO that co-express both IGF-1R and IR.
  • OSI-906 under HGF-stimulated conditions, only OSI-906, and not the IGF-1R specific antibody MAB391, synergized with PHA-665752 to inhibit phospho- AKT/PRAS40 in GEO cells, Figure 3B.
  • HGF human tumors in situ
  • HGF would likely be derived from infiltrating stromal cells such as fibroblasts.
  • OSI-906 alone or in combination with PHA-665752
  • conditioned media derived from two human lung fibroblast cell lines MRC-5 and WI-38.
  • the conditioned media from both MRC-5 and WI-38 cells contained high concentrations of HGF ligand (>7ng/ml), whereas the conditioned media from GEO tumor cells did not (0.2ng/ml), Figure 3D.
  • Phospho- MET was increased when GEO tumor cells were treated with conditioned media from either fibroblast cell line. Consistent with results obtained herein with recombinant HGF, treatment of GEO tumor cells with conditioned media from either HGF- expressing fibroblast cell line resulted in reduced ability of OSI-906 to inhibit AKT signaling. In the presence of the fibroblast medias, we saw more complete inhibition of phospho-AKT7PRAS40 when OSI-906 was combined with PHA compared to either inhibitor individually, Figure 3D. Treatment with the conditioned medias also resulted in increased phospho-ER , which was suppressed by PHA.
  • RTK signaling controls tumor cell proliferation and resistance to apoptosis (1, 2, 4).
  • the tumorigenic properties of receptors within the EGF, HGF, and IGF axes are well established in preclinical models, and this understanding has spurred clinical evaluation of drugs targeting these RTKs.
  • Resistance to EGFR inhibitors can be mediated by a gain in signaling through either the IGF-IR/IR or MET axes, and combining EGFR inhibitors with other agents targeting IGF-IR/IR or MET results in enhanced sensitivity in a variety of preclinical models (19, 25, 26, 38-40). Evaluation of EGFR inhibitors with IGF-IR IR and MET inhibitors is currently underway in clinical studies, and emerging clinical data show promise for enhanced efficacy of an EGFR tyrosine kinase inhibitor in combination with a MET tyrosine kinase inhibitor (30).
  • MET signaling can contribute to reduced sensitivity to not only to EGFR inhibitors but also to IGF-IR/IR inhibitors.
  • EGFR, MET, and IGF-IR/IR are coordinately expressed and activated in several human tumor cell lines. Sensitivity to tyrosine kinase inhibitors of either EGFR (erlotinib) or IGF-IR/IR (OSI-906) was associated with an epithelial phenotype.
  • mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
  • mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.
  • IGF Insulin-like growth factor (e.g.
  • IGF-1, IGF-2); IGF- 1R Insulin- like growth factor 1 receptor
  • EGF epidermal growth factor
  • EGFR epidermal growth factor receptor
  • EMT epithelial-to- mesenchymal transition
  • NSCL non-small cell lung
  • NSCLC non-small cell lung cancer
  • HNSCC or SCCHN head and neck squamous cell carcinoma
  • CRC colorectal cancer
  • MBC metastatic breast cancer
  • PaCa pancreatic cancer
  • Brk Breast tumor kinase (also known as protein tyrosine kinase 6 (PTK6)); FCS, fetal calf serum
  • LC liquid chromatography
  • MS mass spectrometry
  • EGFR EGFR
  • Akt IGF-1R
  • IR IR
  • ERK ERK
  • S6 etc PBS
  • PBS phosphate -buffered saline
  • RTK Receptor Tyrosine Kinase
  • TGI tumor growth inhibition
  • WFI Water for Injection
  • SDS sodium dodecyl sulfate
  • ErbB2 "v-erb-b2 erythroblastic leukemia viral oncogene homolog 2", also known as HER-2
  • ErbB3, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3
  • ErbB4 "v-erb-b2 erythroblastic leukemia viral oncogene homolog 4", also known as HER-4
  • FGFR Fibroblast Growth Factor Receptor
  • MET met proto- oncogene (a.k.a.

Abstract

La présente invention concerne une méthode de traitement de tumeurs ou de métastases tumorales, chez un patient, qui comporte l'administration audit patient simultanément ou séquentiellement d'une quantité thérapeutiquement efficace d'une combinaison d'un inhibiteur de la signalisation par kinase MET (par exemple un inhibiteur de kinase MET à petite molécule, un anticorps anti-MET ou une protéine de liaison à HGF) et d'un inhibiteur de la signalisation par IGF-1R (par exemple un inhibiteur de kinase IGF-1R à petite molécule (par exemple OSI-906), un anticorps anti-IFG-1R ou une ou plusieurs protéines de liaison à IGF (par exemple IGFBP3)). La présente invention concerne également une composition pharmaceutique comportant une combinaison d'un inhibiteur de la signalisation par kinase MET et d'un inhibiteur de la signalisation par IGF-1R, avec un vecteur de qualité pharmaceutique. La présente invention concerne également des procédés ou des compositions où les activités inhibitrices de la signalisation par kinase MET et de la signalisation par kinase IGF-1R résident dans la même molécule.
PCT/US2013/035358 2012-04-06 2013-04-05 Polythérapie antinéoplasique WO2013152252A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261621054P 2012-04-06 2012-04-06
US61/621,054 2012-04-06

Publications (1)

Publication Number Publication Date
WO2013152252A1 true WO2013152252A1 (fr) 2013-10-10

Family

ID=48142096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/035358 WO2013152252A1 (fr) 2012-04-06 2013-04-05 Polythérapie antinéoplasique

Country Status (1)

Country Link
WO (1) WO2013152252A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869668B2 (en) 2014-08-26 2018-01-16 Samsung Electronics Co., Ltd. PDGF as a biomarker for predicting resistance or effect of c-Met targeting drugs
US10064939B2 (en) 2014-11-21 2018-09-04 Samsung Electronics Co., Ltd. Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers
US11142578B2 (en) 2016-11-16 2021-10-12 Regeneron Pharmaceuticals, Inc. Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof
WO2022115946A1 (fr) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Applications thérapeutiques d'antagonistes du récepteur du facteur de croissance de type insuline 1 (igf-1)
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof

Citations (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035A (en) 1978-11-24 1985-03-05 Hoffmann-La Roche Inc. Protein purification process and product
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
WO1990005719A1 (fr) 1988-11-23 1990-05-31 British Bio-Technology Limited Inhibiteurs de collagenase a base d'acide hydroxamique
US5132408A (en) 1986-04-22 1992-07-21 The Salk Institute For Biological Studies Fibroblast growth factor antagonists
WO1992020642A1 (fr) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
EP0520722A1 (fr) 1991-06-28 1992-12-30 Zeneca Limited Préparations thérapeutiques contenant des dérivés de quinazoline
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
EP0564409A1 (fr) 1992-04-03 1993-10-06 Ciba-Geigy Ag Dérivés de pyrimidine et procédé pour leur préparation
EP0566226A1 (fr) 1992-01-20 1993-10-20 Zeneca Limited Dérivés de quinazoline
EP0606046A1 (fr) 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substitués dérivés d'acides hydroxamic
WO1995009847A1 (fr) 1993-10-01 1995-04-13 Ciba-Geigy Ag Derives pyrimidineamine et leurs procedes de preparation
US5418135A (en) 1990-12-21 1995-05-23 Creative Biomolecules, Inc. Method of inhibiting binding of PDGF to a PDGF receptor by biosynthetic PDGF antagonists
JPH07133280A (ja) 1993-11-09 1995-05-23 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
WO1995019774A1 (fr) 1994-01-25 1995-07-27 Warner-Lambert Company Composes bicycliques permettant d'inhiber les tyrosine-kinases de la famille du recepteur du facteur de croissance de l'epiderme
WO1995019970A1 (fr) 1994-01-25 1995-07-27 Warner-Lambert Company Composes tricycliques pouvant inhiber les tyrosines kinases de la famille des recepteurs du facteur de croissance epidermique
WO1995021613A1 (fr) 1994-02-09 1995-08-17 Sugen, Inc. Composes destines au traitement de troubles associes a la vasculogenese et/ou a l'angiogenese
EP0682027A1 (fr) 1994-05-03 1995-11-15 Ciba-Geigy Ag Dérivés de la pyrrolopyrimidine avec une activité anti-proliférative
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5476851A (en) 1994-09-08 1995-12-19 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1996027583A1 (fr) 1995-03-08 1996-09-12 Pfizer Inc. Derives de l'acide arylsulfonylamino hydroxamique
WO1996030347A1 (fr) 1995-03-30 1996-10-03 Pfizer Inc. Derives de quinazoline
WO1996031510A1 (fr) 1995-04-03 1996-10-10 Novartis Ag Derives de pyrazole et leurs procedes de preparation
WO1996033172A1 (fr) 1995-04-20 1996-10-24 Pfizer Inc. Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
WO1996033980A1 (fr) 1995-04-27 1996-10-31 Zeneca Limited Derives de quinazoline
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1997002266A1 (fr) 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
WO1997003288A1 (fr) 1995-07-07 1997-01-30 Bonus Energy A/S Cadre de base pour bati de moulin a vent et moulin a vent pourvu de ce cadre de base
US5618837A (en) 1995-06-07 1997-04-08 Zymogenetics, Inc. PDGF antagonists III
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
WO1997013760A1 (fr) 1995-10-11 1997-04-17 Glaxo Group Limited Composes condenses tricycliques et compositions pharmaceutiques les contenant
WO1997013771A1 (fr) 1995-10-11 1997-04-17 Glaxo Group Limited Composes hetero-aromatiques bicycliques utilises comme inhibiteurs de proteine tyrosine kinase
WO1997015666A1 (fr) 1995-10-23 1997-05-01 The Children's Medical Center Corporation Compositions therapeutiques anti-angiogenese et procedes associes
WO1997019065A1 (fr) 1995-11-20 1997-05-29 Celltech Therapeutics Limited 2-anilinopyrimidines substituees utiles en tant qu'inhibiteurs de proteine kinase
EP0780386A1 (fr) 1995-12-20 1997-06-25 F. Hoffmann-La Roche Ag Inhibiteurs de métalloprotéases matricielles
WO1997022596A1 (fr) 1995-12-18 1997-06-26 Zeneca Limited Derives de quinazoline
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
WO1997027199A1 (fr) 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
EP0787772A2 (fr) 1996-01-30 1997-08-06 Dow Corning Toray Silicone Company Ltd. Compositions d'élastomère de silicone
WO1997028161A1 (fr) 1996-02-01 1997-08-07 Novartis Ag Nouvelles pyrrolo(2,3-d)pyrimidines et leur utilisation en tant qu'inhibiteurs de tyrosine kinase
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1997030044A1 (fr) 1996-02-14 1997-08-21 Zeneca Limited Composes de quinazoline
WO1997030034A1 (fr) 1996-02-14 1997-08-21 Zeneca Limited Derives de la quinazoline servant d'agents antitumoraux
US5662904A (en) 1991-03-28 1997-09-02 The Victoria University Of Manchester Anti-scarring compositions comprising growth factor neutralizing antibodies
WO1997032880A1 (fr) 1996-03-06 1997-09-12 Dr. Karl Thomae Gmbh PYRIMIDO[5,4-d]PYRIMIDINES, MEDICAMENTS CONTENANT CES COMPOSES, LEUR UTILISATION ET PROCEDE DE FABRICATION ASSOCIE
WO1997032881A1 (fr) 1996-03-06 1997-09-12 Dr. Karl Thomae Gmbh Derives de 4-amino-pyrimidine, medicaments contenant ces composes, leur utilisation et leur procede de production
WO1997032856A1 (fr) 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
US5668264A (en) 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
WO1997034895A1 (fr) 1996-03-15 1997-09-25 Novartis Ag NOUVELLES N-7-HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINES ET LEUR UTILISATION
US5674685A (en) 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5674892A (en) 1994-10-28 1997-10-07 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
WO1997038983A1 (fr) 1996-04-12 1997-10-23 Warner-Lambert Company Inhibiteurs irreversibles de tyrosine kinases
WO1997038994A1 (fr) 1996-04-13 1997-10-23 Zeneca Limited Derives de quinazoline
US5693610A (en) 1994-08-25 1997-12-02 Kureha Chemical Industry Co., Ltd. Binding agent for growth factor
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
WO1997049688A1 (fr) 1996-06-24 1997-12-31 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
EP0818442A2 (fr) 1996-07-12 1998-01-14 Pfizer Inc. Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
WO1998002437A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998002438A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998002434A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998003516A1 (fr) 1996-07-18 1998-01-29 Pfizer Inc. Composes a base de phosphinate inhibiteurs des metalloproteases matricielles
WO1998007726A1 (fr) 1996-08-23 1998-02-26 Novartis Ag Pyrrolopyrimidines substituees et procede pour leur preparation
WO1998007697A1 (fr) 1996-08-23 1998-02-26 Pfizer Inc. Derives de l'acide arylsulfonylamino hydroxamique
WO1998007695A1 (fr) 1996-08-23 1998-02-26 Sugen, Inc. Banques combinatoires d'indolinone, produits et procedes associes pour traiter des maladies
US5723594A (en) 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5731326A (en) 1995-06-30 1998-03-24 Zymogenetics, Inc. PDGF antagonists II
WO1998014449A1 (fr) 1996-10-02 1998-04-09 Novartis Ag Derives de pyrazole condenses et procedes pour leur preparation
WO1998014450A1 (fr) 1996-10-02 1998-04-09 Novartis Ag Derives de pyrimidine et procedes de preparation de ces derniers
WO1998014451A1 (fr) 1996-10-02 1998-04-09 Novartis Ag Derive de pyrazole condense et procede pour sa preparation
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
WO1998017662A1 (fr) 1996-10-18 1998-04-30 Novartis Ag Derives d'heterocyclyle bicyclique a substitution phenyle et utilisation de ces derives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1998030566A1 (fr) 1997-01-06 1998-07-16 Pfizer Inc. Derives de sulfone cyclique
US5789427A (en) 1994-03-07 1998-08-04 Sugen, Inc. Methods and compositions for inhibiting cell proliferative disorders
WO1998033798A2 (fr) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3d]pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
WO1998033768A1 (fr) 1997-02-03 1998-08-06 Pfizer Products Inc. Derives d'acide arylsulfonylaminohydroxamique
US5792783A (en) 1995-06-07 1998-08-11 Sugen, Inc. 3-heteroaryl-2-indolinone compounds for the treatment of disease
WO1998034918A1 (fr) 1997-02-11 1998-08-13 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
WO1998034915A1 (fr) 1997-02-07 1998-08-13 Pfizer Inc. Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1998050356A1 (fr) 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
WO1998054093A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5872218A (en) 1991-01-31 1999-02-16 Cor Therapeutics, Inc. Human platelet-derived growth factor receptor extracellular domain antibodies
WO1999007701A1 (fr) 1997-08-05 1999-02-18 Sugen, Inc. Derives de quinoxaline tricyclique utiles en tant qu'inhibiteurs de proteine tyrosine kinase
WO1999007675A1 (fr) 1997-08-08 1999-02-18 Pfizer Products Inc. Derives de l'acide aryloxyarylsulfonylamino hydroxamique
US5877305A (en) 1992-02-06 1999-03-02 Chiron Corporation DNA encoding biosynthetic binding protein for cancer marker
WO1999010349A1 (fr) 1997-08-22 1999-03-04 Zeneca Limited Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
WO1999016755A1 (fr) 1997-09-26 1999-04-08 Merck & Co., Inc. Nouveaux inhibiteurs de l'angiogenese
WO1999024440A1 (fr) 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
WO1999029667A1 (fr) 1997-12-05 1999-06-17 Pfizer Limited Derives d'acide hydroxamique utilises comme inhibiteurs de metalloproteases matricielles
WO1999032620A1 (fr) 1997-12-22 1999-07-01 Forssmann Wolf Georg Fragments de proteine liant le facteur de croissance de substances apparentees a l'insuline et leur utilisation
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
WO1999035146A1 (fr) 1998-01-12 1999-07-15 Glaxo Group Limited Composes heteroaromatiques bicycliques agissant comme inhibiteurs de la tyrosine kinase
WO1999035132A1 (fr) 1998-01-12 1999-07-15 Glaxo Group Limited Composes heterocycliques
EP0931788A2 (fr) 1998-01-27 1999-07-28 Pfizer Limited Inhibiteurs de la métalloprotéinase
US5932580A (en) 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
US5952304A (en) 1993-10-22 1999-09-14 Trigen Limited Platelet-derived growth factor analogues
WO1999052910A1 (fr) 1998-04-10 1999-10-21 Pfizer Products Inc. Derives bicycliques de l'acide hydroxamique
WO1999052889A1 (fr) 1998-04-10 1999-10-21 Pfizer Products Inc. Hydroxamides de l'acide (4-arylsulfonylamino)-tetrahydropyrane-4-carboxylique
US5976534A (en) 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
WO1999060023A1 (fr) 1998-05-15 1999-11-25 Imclone Systems Incorporated Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
WO1999061422A1 (fr) 1998-05-29 1999-12-02 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
WO1999062890A1 (fr) 1998-06-04 1999-12-09 Pfizer Products Inc. Derives isothiazole utiles en tant qu'agents anticancereux
WO1999063086A2 (fr) 1998-06-01 1999-12-09 Celtrix Pharmaceuticals, Inc. Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide
WO2000015781A1 (fr) 1998-09-11 2000-03-23 Eli Lilly And Company Antagonistes du facteur de croissance des fibroblastes
WO2000017203A1 (fr) 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines utilisees comme inhibiteurs de proteines kinases
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
WO2000023469A2 (fr) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments du facteur de croissance proche de l'insuline et de la proteine de fixation du facteur de croissance proche de l'insuline, et utilisations de ces fragments
EP1004578A2 (fr) 1998-11-05 2000-05-31 Pfizer Products Inc. Dérivés d'hydroxamide de l'acide 5-oxo-pyrrolidine-2-carboxylique
US6071935A (en) 1996-06-27 2000-06-06 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
WO2000035455A1 (fr) 1998-12-15 2000-06-22 Telik, Inc. Urees heteroaryle-aryle utilisees comme antagonistes du recepteur igf-1
US6080769A (en) 1997-12-30 2000-06-27 Pfizer Inc. Imidazolidin-4-one derivatives useful as anticancer agents
WO2000046380A2 (fr) 1999-02-08 2000-08-10 Chiron Corporation Fusion du recepteur du facteur de croissance des fibroblastes avec une immunoglobuline
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US6150377A (en) 1998-08-27 2000-11-21 Pfizer Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
WO2000071129A1 (fr) 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazines inhibiteurs de kinases
US6194438B1 (en) 1998-12-02 2001-02-27 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives
US6207816B1 (en) 1995-06-02 2001-03-27 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to growth factors
US6207667B1 (en) 1996-10-01 2001-03-27 Kyowa Hakko Kogyo Co., Ltd. 1,3 diazines with platelet-derived growth factor receptor inhibitory activity
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
WO2001032653A1 (fr) 1999-11-04 2001-05-10 Cephalon, Inc. Pyrazolones heterocycliques substitues
WO2001034574A1 (fr) 1999-11-11 2001-05-17 Osi Pharmaceuticals, Inc. Polymorphe stable de chlorhydrate de n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, et methodes de production et utilisations pharmaceutiques dudit polymorphe
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2001040217A1 (fr) 1999-11-30 2001-06-07 Pfizer Products Inc. Nouveaux derives benzoimidazole convenant comme agents antiproliferatifs
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6251905B1 (en) 1994-07-15 2001-06-26 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US6258824B1 (en) 1999-02-11 2001-07-10 Pfizer Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
WO2001070977A2 (fr) 2000-03-22 2001-09-27 Amgen, Inc. Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
WO2001072751A1 (fr) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
WO2002012238A2 (fr) 2000-08-04 2002-02-14 Warner-Lambert Company 2-(4-pyridyl)amino-6-dialcoxyphenyl-pyrido[2,3-d]pyrimidine-7-ones
US6358954B1 (en) 1999-11-09 2002-03-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6465449B1 (en) 1999-01-27 2002-10-15 Pfizer Inc. Heteroaromatic bicyclic derivatives useful as anticancer agents
US6468529B1 (en) 1995-06-02 2002-10-22 Genentech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6479513B2 (en) 2000-01-21 2002-11-12 Pfizer Inc. Anticancer compound and enantiomer separation method useful for synthesizing said compound
WO2002092599A1 (fr) 2001-05-14 2002-11-21 Novartis Ag Derives 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine
WO2002098914A2 (fr) 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Mutants de proteines de liaison du facteur de croissance insulinomimetique (igf) et methodes de production d'antagonistes
US6495564B1 (en) 1998-08-27 2002-12-17 Pfizer Inc. Quinolin-2-one derivatives useful as anticancer agents
WO2002102804A1 (fr) 2001-06-19 2002-12-27 Axelar Ab Nouvelle utilisation de cyclolignans specifiques
WO2002102972A2 (fr) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Anticorps bloquant l'activation d'un recepteur a activite proteine tyrosine kinase, procedes de criblage et utilisations associes
WO2003000660A1 (fr) 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive
WO2003013541A1 (fr) 2001-08-07 2003-02-20 Novartis Ag Derives de la 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine
WO2003015282A2 (fr) 2001-08-10 2003-02-20 Iroc Technologies Ensemble de circuits electroniques comportant des moyens de decontamination de parties contaminees par des erreurs
US6524347B1 (en) 1997-05-28 2003-02-25 Avantis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6528526B1 (en) 1997-05-28 2003-03-04 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
WO2003018021A1 (fr) 2001-08-22 2003-03-06 Amgen Inc. Derives pyrimidinyle 2,4-bisusbtitues utiles en tant qu'agents anticancereux
WO2003018022A1 (fr) 2001-08-22 2003-03-06 Amgen Inc. Derives de 2-amino-4-heteroarylaminopyrimidine pouvant etre utilises pour traiter le cancer
US6537988B2 (en) 2000-03-27 2003-03-25 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer
WO2003025019A1 (fr) 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anticorps anti-pdgf et procedes de production d'anticorps mis au point
WO2003024967A2 (fr) 2001-09-19 2003-03-27 Aventis Pharma S.A. Composes chimiques
US6541481B2 (en) 1999-01-27 2003-04-01 Pfizer Inc Substituted bicyclic derivatives useful as anticancer agents
WO2003035614A2 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
WO2003035615A2 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
WO2003035619A1 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
WO2003035616A2 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
WO2003048133A1 (fr) 2001-12-07 2003-06-12 Astrazeneca Ab Derives de pyrimidine utilises en tant que modulateurs du recepteur de du facteur 1 de croissance (igf-i) semblable a l'insuline
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
US20030125370A1 (en) 2001-05-30 2003-07-03 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6596735B1 (en) 1999-11-30 2003-07-22 Pfizer Inc Quinoline derivatives useful for inhibiting farnesyl protein transferase
WO2003068265A1 (fr) 2002-02-14 2003-08-21 Dana-Farber Cancer Institute Inc. Procedes et compositions pour traiter des etats hyperproliferatifs
WO2003078404A1 (fr) 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
WO2003087026A1 (fr) 2002-04-18 2003-10-23 F. Hoffmann-La Roche Ag 2-(2,6-dichlorophenyl)-diarylimidazoles
WO2003097641A2 (fr) 2002-05-21 2003-11-27 Novartis Ag Derives 1h-imidazo[4,5-c]quinoline servant au traitement de maladies dependant de proteines kinases
WO2003099771A2 (fr) 2002-05-29 2003-12-04 Novartis Ag Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
WO2004001059A2 (fr) 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Inhibiteurs heterocycliques de kinases
WO2004005282A1 (fr) 2002-07-09 2004-01-15 Novartis Ag Derives de phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US20040018191A1 (en) 2002-05-24 2004-01-29 Schering Corporation Neutralizing human anti-IGFR antibody
WO2004009601A1 (fr) 2002-07-19 2004-01-29 Bristol-Myers Squibb Company Inhibiteurs de l'azaindole kinase
WO2004013145A1 (fr) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Composes de pyrrolotriazine inhibiteurs de kinase
WO2004018472A2 (fr) 2002-08-14 2004-03-04 F. Hoffmann-La Roche Ag Composes pyrimido presentant une activite antiproliferative
WO2004041822A1 (fr) 2002-11-04 2004-05-21 F. Hoffmann-La Roche Ag Derives de pyrimido[4,5-d]pyrimidine a activite anticancereuse
WO2004046152A1 (fr) 2002-11-18 2004-06-03 F. Hoffmann La Roche Ag Diazyinopyrimidines
US20040110758A1 (en) 2002-10-01 2004-06-10 Player Mark R. 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
WO2004076412A2 (fr) 2003-02-26 2004-09-10 Sugen, Inc. Composes d'aminoheteroaryle utilises en tant qu'inhibiteurs de proteine kinase
US20040198750A1 (en) 2003-04-03 2004-10-07 Jeremy Green Compositions useful as inhibitors of protein kinases
US20040204427A1 (en) 2003-04-10 2004-10-14 Yi Chen Pyrimido compounds having antiproliferative activity
US20040202651A1 (en) 2003-02-13 2004-10-14 Pfizer Inc. Uses of anti-insulin-like growth factor 1 receptor antibodies
WO2004093812A2 (fr) 2003-04-22 2004-11-04 Irm Llc Composes induisant une differentiation neuronale dans des cellules souche embryonnaires
US20050009845A1 (en) 2001-12-19 2005-01-13 Caferro Thomas R. Thienopyrimidine compounds as protein tyrosine kinase inhibitors
WO2005004808A2 (fr) 2003-07-02 2005-01-20 Sugen, Inc. Composes tetracycliques utilises comme inhibiteurs de c-met
WO2005011597A2 (fr) 2003-07-29 2005-02-10 Irm Llc Composes et compositions utilises en tant qu'inhibiteurs des proteines kinases
WO2005012359A2 (fr) 2003-08-01 2005-02-10 Genentech, Inc. Anticorps anti-vegf
WO2005017107A2 (fr) 2003-07-18 2005-02-24 Amgen Inc. Agents de liaison specifiques se liant a un facteur de croissance hepatocyte
WO2005016382A1 (fr) 2003-08-04 2005-02-24 Pfizer Products Inc. Anticorps diriges contre c-met
WO2005021531A1 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs d'un ensemble de benzimidazolyle c n substitue
WO2005021544A2 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
WO2005021537A1 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs de c-kit pyrazolyle-amidyle-benzimidazolyle n-substitues
WO2005028448A1 (fr) 2003-09-12 2005-03-31 Merck Patent Gmbh Derives de benzyl-benzimidazolyle
WO2005030140A2 (fr) 2003-09-26 2005-04-07 Exelixis, Inc. Modulateurs de c-met et procede d'utilisation
US20050075340A1 (en) 2003-07-02 2005-04-07 Sugen, Inc. Triazolotriazine compounds and uses thereof
WO2005037836A2 (fr) 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazopyrazines utilisees comme inhibiteurs de la tyrosine kinase
US20050101650A1 (en) 2003-08-15 2005-05-12 Alex Aronov Pyrrole compositions useful as inhibitors of c-Met
WO2005054246A2 (fr) 2003-12-04 2005-06-16 Merck Patent Gmbh Derives d'amine
US20050136063A1 (en) 2003-11-21 2005-06-23 Schering Corporation Anti-IGFR antibody therapeutic combinations
US20050148574A1 (en) 2003-09-24 2005-07-07 Alex Aronov Imidazole compositions useful as inhibitors of protein kinases
US20050154014A1 (en) 2003-01-06 2005-07-14 Jason Bloxham (2-carboxamido)(3-amino) thiophene compounds
WO2005066211A2 (fr) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Utilisation des recepteurs 1, 2, 3 et 4 du facteur de croissance des fibroblastes comme cibles pour une intervention therapeutique
WO2005070891A2 (fr) 2004-01-23 2005-08-04 Amgen Inc Composes et leurs procedes d'utilisation
WO2005080393A1 (fr) 2004-02-14 2005-09-01 Irm Llc Composes et compositions tenant lieu d'inhibiteurs de la proteine kinase
US6949563B2 (en) 2003-01-06 2005-09-27 Graham Michael Wynne (2-carboxamido)(3-amino)thiophene compounds
US20050245547A1 (en) 2004-01-23 2005-11-03 Tae-Seong Kim Compounds and methods of use
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
WO2005121125A1 (fr) 2004-06-09 2005-12-22 Pfizer Inc. Composes heteroaryle a liaison ether
US20060009493A1 (en) 2003-07-02 2006-01-12 Sugen, Inc. Indolinone hydrazides as c-Met inhibitors
US20060009453A1 (en) 2004-05-07 2006-01-12 Geuns-Meyer Stephanie D Protein kinase modulators and method of use
WO2006015371A2 (fr) 2004-08-05 2006-02-09 Genentech, Inc. Antagonistes anti-cmet humanises
WO2006014325A2 (fr) 2004-07-02 2006-02-09 Exelixis, Inc. Modulateurs de c-met et leur methode d'utilisation
WO2006021881A2 (fr) 2004-08-26 2006-03-02 Pfizer Inc. Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase
WO2006021886A1 (fr) 2004-08-26 2006-03-02 Pfizer Inc. Composes aminoheteroaryles en tant qu'inhibiteurs des proteines tyrosine kinases
WO2006042599A1 (fr) 2004-10-13 2006-04-27 Merck Patent Gmbh Derives de phenyluree
US7037487B2 (en) 2000-09-27 2006-05-02 Sitke Aygen Method for diagnosing lactose intolerance and diagnostic kit for performing the method
WO2006050779A1 (fr) 2004-11-10 2006-05-18 Merck Patent Gmbh Derives de la n,n'-diphenyluree convenant comme inhibiteurs de kinases
WO2006050800A1 (fr) 2004-11-10 2006-05-18 Merck Patent Gmbh Derives de 4-amino-5-oxo-8-phenyl-5h-pyrido[2,3-d]-pyrimidine utilises en tant qu'inhibiteurs des tyrosines kinases et des kinases raf pour traiter des tumeurs
US20060148748A1 (en) 1999-07-29 2006-07-06 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006094600A1 (fr) 2005-03-10 2006-09-14 Merck Patent Gmbh Derives de tetrahydro-pyrrolo-quinoleine substitues servant de modulateurs de kinase, plus specialement de tyrosine kinases et de raf-kinases
WO2006105844A1 (fr) 2005-04-04 2006-10-12 Merck Patent Gmbh Derive de pyrazole
WO2006108482A1 (fr) 2005-04-14 2006-10-19 Merck Patent Gmbh Dérivés de purine en tant qu'inhibiteurs de l'activité de tyrosine kinase réceptrice
US20060235031A1 (en) 2004-04-02 2006-10-19 Arnold Lee D 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2006112479A1 (fr) 2005-04-19 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. Composé hétérocyclique azoté
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
WO2006134989A1 (fr) 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. Composé hétérocyclique azoté
WO2007009773A1 (fr) 2005-07-21 2007-01-25 Novartis Ag Derives de pyrazolo[1,5a]pyrimidin-7-yl-amine utilises en tant qu'inhibiteurs des proteines kinases
WO2007014123A2 (fr) 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions et procedes de traitement de maladies a l'aide de proteines de fusion fgfr
WO2007017107A1 (fr) 2005-07-29 2007-02-15 System Plast S.P.A. Chaîne en métal pour convoyeurs à chaîne
WO2007019884A1 (fr) 2005-08-16 2007-02-22 F. Hoffmann-La Roche Ag Nouveaux amides de l'acide 4-amino-thiéno[3,2-c]pyridine-7-carboxylique
US7192738B2 (en) 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
WO2007063816A1 (fr) 2005-11-30 2007-06-07 Toray Industries, Inc. Pâte de verre, procédé de fabrication d'un afficheur en utilisant celle-ci et afficheur
WO2007103308A2 (fr) 2006-03-07 2007-09-13 Array Biopharma Inc. Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation
WO2007115049A2 (fr) 2006-04-01 2007-10-11 Galaxy Biotech, Llc Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes
WO2007126799A2 (fr) 2006-03-30 2007-11-08 Novartis Ag Compositions et procédés d'utilisation associés à des anticorps de c-met
WO2007143098A2 (fr) 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
US7371378B2 (en) 2003-08-13 2008-05-13 Pfizer Inc. Modified human IGF-IR antibodies
US7408043B2 (en) 2003-11-11 2008-08-05 National Cancer Center Neutralizing antibody against HGF
WO2009002521A2 (fr) 2007-06-25 2008-12-31 Amgen Inc. Compositions d'agents de liaison spécifiques vis-à-vis du facteur de croissance des hépatocytes
WO2009007427A2 (fr) 2007-07-12 2009-01-15 Pierre Fabre Medicament Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
WO2009100282A1 (fr) 2008-02-06 2009-08-13 Osi Pharmaceuticals, Inc. Furo-[3,2-c]pyridines et thiéno[3,2-c]pyridines
WO2009099982A1 (fr) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. Inhibiteurs de 2-aminopyridine kinases
US20090226443A1 (en) 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and egfr antagonists
WO2010059771A1 (fr) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Pyrrolo[2,3-b]-pyridines et pyrrolo[2,3-b]-pyrazines substituées
WO2011109593A1 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC 5-aminopyrrolo/pyrazolopyridines substituées
US20110262525A1 (en) 2006-12-13 2011-10-27 Schering Corporation Methods of treatment
WO2011143645A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinase bicycliques fusionnés

Patent Citations (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035A (en) 1978-11-24 1985-03-05 Hoffmann-La Roche Inc. Protein purification process and product
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US5132408A (en) 1986-04-22 1992-07-21 The Salk Institute For Biological Studies Fibroblast growth factor antagonists
WO1990005719A1 (fr) 1988-11-23 1990-05-31 British Bio-Technology Limited Inhibiteurs de collagenase a base d'acide hydroxamique
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US5833986A (en) 1989-02-09 1998-11-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting the growth of neoplasia using a monoclonal antibody against α platelet derived growth factor receptor
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5668264A (en) 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5674685A (en) 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5418135A (en) 1990-12-21 1995-05-23 Creative Biomolecules, Inc. Method of inhibiting binding of PDGF to a PDGF receptor by biosynthetic PDGF antagonists
US5872218A (en) 1991-01-31 1999-02-16 Cor Therapeutics, Inc. Human platelet-derived growth factor receptor extracellular domain antibodies
US5662904A (en) 1991-03-28 1997-09-02 The Victoria University Of Manchester Anti-scarring compositions comprising growth factor neutralizing antibodies
WO1992020642A1 (fr) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
US5795889A (en) 1991-05-10 1998-08-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6057320A (en) 1991-05-10 2000-05-02 Aventis Pharmaceuticals Products Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0520722A1 (fr) 1991-06-28 1992-12-30 Zeneca Limited Préparations thérapeutiques contenant des dérivés de quinazoline
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
EP0566226A1 (fr) 1992-01-20 1993-10-20 Zeneca Limited Dérivés de quinazoline
US5877305A (en) 1992-02-06 1999-03-02 Chiron Corporation DNA encoding biosynthetic binding protein for cancer marker
JPH0687834A (ja) 1992-04-03 1994-03-29 Ciba Geigy Ag ピリミジン誘導体及びその製法
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0564409A1 (fr) 1992-04-03 1993-10-06 Ciba-Geigy Ag Dérivés de pyrimidine et procédé pour leur préparation
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
EP0606046A1 (fr) 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substitués dérivés d'acides hydroxamic
US5976534A (en) 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
WO1995009847A1 (fr) 1993-10-01 1995-04-13 Ciba-Geigy Ag Derives pyrimidineamine et leurs procedes de preparation
US5952304A (en) 1993-10-22 1999-09-14 Trigen Limited Platelet-derived growth factor analogues
US6350731B1 (en) 1993-10-22 2002-02-26 Trigen Limited Platelet-derived growth factor analogues
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH07133280A (ja) 1993-11-09 1995-05-23 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
US5932602A (en) 1994-01-07 1999-08-03 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5958959A (en) 1994-01-07 1999-09-28 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5990141A (en) 1994-01-07 1999-11-23 Sugen Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5700822A (en) 1994-01-07 1997-12-23 The Regents Of The University Of California Treatment of platelet derived growth factor related disorders such as cancers
WO1995019970A1 (fr) 1994-01-25 1995-07-27 Warner-Lambert Company Composes tricycliques pouvant inhiber les tyrosines kinases de la famille des recepteurs du facteur de croissance epidermique
WO1995019774A1 (fr) 1994-01-25 1995-07-27 Warner-Lambert Company Composes bicycliques permettant d'inhiber les tyrosine-kinases de la famille du recepteur du facteur de croissance de l'epiderme
WO1995021613A1 (fr) 1994-02-09 1995-08-17 Sugen, Inc. Composes destines au traitement de troubles associes a la vasculogenese et/ou a l'angiogenese
US5789427A (en) 1994-03-07 1998-08-04 Sugen, Inc. Methods and compositions for inhibiting cell proliferative disorders
EP0682027A1 (fr) 1994-05-03 1995-11-15 Ciba-Geigy Ag Dérivés de la pyrrolopyrimidine avec une activité anti-proliférative
US6251905B1 (en) 1994-07-15 2001-06-26 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US5693610A (en) 1994-08-25 1997-12-02 Kureha Chemical Industry Co., Ltd. Binding agent for growth factor
US5476851A (en) 1994-09-08 1995-12-19 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5674892A (en) 1994-10-28 1997-10-07 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5728726A (en) 1994-10-28 1998-03-17 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
WO1996027583A1 (fr) 1995-03-08 1996-09-12 Pfizer Inc. Derives de l'acide arylsulfonylamino hydroxamique
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1996030347A1 (fr) 1995-03-30 1996-10-03 Pfizer Inc. Derives de quinazoline
WO1996031510A1 (fr) 1995-04-03 1996-10-10 Novartis Ag Derives de pyrazole et leurs procedes de preparation
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
WO1996033172A1 (fr) 1995-04-20 1996-10-24 Pfizer Inc. Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
WO1996033980A1 (fr) 1995-04-27 1996-10-31 Zeneca Limited Derives de quinazoline
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6468529B1 (en) 1995-06-02 2002-10-22 Genentech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6207816B1 (en) 1995-06-02 2001-03-27 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to growth factors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5834504A (en) 1995-06-07 1998-11-10 Sugen, Inc. 3-(2'-halobenzylidenyl)-2-indolinone compounds for the treatment of disease
US5618837A (en) 1995-06-07 1997-04-08 Zymogenetics, Inc. PDGF antagonists III
US6582918B2 (en) 1995-06-07 2003-06-24 Gilead Sciences, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US5792783A (en) 1995-06-07 1998-08-11 Sugen, Inc. 3-heteroaryl-2-indolinone compounds for the treatment of disease
US5883113A (en) 1995-06-07 1999-03-16 Sugen, Inc. 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
US5886020A (en) 1995-06-07 1999-03-23 Sugen, Inc. 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
US5723594A (en) 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5731326A (en) 1995-06-30 1998-03-24 Zymogenetics, Inc. PDGF antagonists II
WO1997002266A1 (fr) 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
WO1997003288A1 (fr) 1995-07-07 1997-01-30 Bonus Energy A/S Cadre de base pour bati de moulin a vent et moulin a vent pourvu de ce cadre de base
WO1997013760A1 (fr) 1995-10-11 1997-04-17 Glaxo Group Limited Composes condenses tricycliques et compositions pharmaceutiques les contenant
WO1997013771A1 (fr) 1995-10-11 1997-04-17 Glaxo Group Limited Composes hetero-aromatiques bicycliques utilises comme inhibiteurs de proteine tyrosine kinase
WO1997015666A1 (fr) 1995-10-23 1997-05-01 The Children's Medical Center Corporation Compositions therapeutiques anti-angiogenese et procedes associes
WO1997019065A1 (fr) 1995-11-20 1997-05-29 Celltech Therapeutics Limited 2-anilinopyrimidines substituees utiles en tant qu'inhibiteurs de proteine kinase
WO1997022596A1 (fr) 1995-12-18 1997-06-26 Zeneca Limited Derives de quinazoline
EP0780386A1 (fr) 1995-12-20 1997-06-25 F. Hoffmann-La Roche Ag Inhibiteurs de métalloprotéases matricielles
WO1997027199A1 (fr) 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
EP0787772A2 (fr) 1996-01-30 1997-08-06 Dow Corning Toray Silicone Company Ltd. Compositions d'élastomère de silicone
WO1997028161A1 (fr) 1996-02-01 1997-08-07 Novartis Ag Nouvelles pyrrolo(2,3-d)pyrimidines et leur utilisation en tant qu'inhibiteurs de tyrosine kinase
WO1997030044A1 (fr) 1996-02-14 1997-08-21 Zeneca Limited Composes de quinazoline
WO1997030034A1 (fr) 1996-02-14 1997-08-21 Zeneca Limited Derives de la quinazoline servant d'agents antitumoraux
WO1997032856A1 (fr) 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
DE19629652A1 (de) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO1997032881A1 (fr) 1996-03-06 1997-09-12 Dr. Karl Thomae Gmbh Derives de 4-amino-pyrimidine, medicaments contenant ces composes, leur utilisation et leur procede de production
WO1997032880A1 (fr) 1996-03-06 1997-09-12 Dr. Karl Thomae Gmbh PYRIMIDO[5,4-d]PYRIMIDINES, MEDICAMENTS CONTENANT CES COMPOSES, LEUR UTILISATION ET PROCEDE DE FABRICATION ASSOCIE
WO1997034895A1 (fr) 1996-03-15 1997-09-25 Novartis Ag NOUVELLES N-7-HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINES ET LEUR UTILISATION
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
WO1997038983A1 (fr) 1996-04-12 1997-10-23 Warner-Lambert Company Inhibiteurs irreversibles de tyrosine kinases
WO1997038994A1 (fr) 1996-04-13 1997-10-23 Zeneca Limited Derives de quinazoline
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1997049688A1 (fr) 1996-06-24 1997-12-31 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
US6071935A (en) 1996-06-27 2000-06-06 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
EP0818442A2 (fr) 1996-07-12 1998-01-14 Pfizer Inc. Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
WO1998002438A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998002437A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998002434A1 (fr) 1996-07-13 1998-01-22 Glaxo Group Limited Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
WO1998003516A1 (fr) 1996-07-18 1998-01-29 Pfizer Inc. Composes a base de phosphinate inhibiteurs des metalloproteases matricielles
WO1998007726A1 (fr) 1996-08-23 1998-02-26 Novartis Ag Pyrrolopyrimidines substituees et procede pour leur preparation
WO1998007697A1 (fr) 1996-08-23 1998-02-26 Pfizer Inc. Derives de l'acide arylsulfonylamino hydroxamique
WO1998007695A1 (fr) 1996-08-23 1998-02-26 Sugen, Inc. Banques combinatoires d'indolinone, produits et procedes associes pour traiter des maladies
US6472391B2 (en) 1996-10-01 2002-10-29 Millennium Pharmaceuticals, Inc. Nitrogen-containing heterocyclic compounds
US6207667B1 (en) 1996-10-01 2001-03-27 Kyowa Hakko Kogyo Co., Ltd. 1,3 diazines with platelet-derived growth factor receptor inhibitory activity
WO1998014450A1 (fr) 1996-10-02 1998-04-09 Novartis Ag Derives de pyrimidine et procedes de preparation de ces derniers
WO1998014449A1 (fr) 1996-10-02 1998-04-09 Novartis Ag Derives de pyrazole condenses et procedes pour leur preparation
WO1998014451A1 (fr) 1996-10-02 1998-04-09 Novartis Ag Derive de pyrazole condense et procede pour sa preparation
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
WO1998017662A1 (fr) 1996-10-18 1998-04-30 Novartis Ag Derives d'heterocyclyle bicyclique a substitution phenyle et utilisation de ces derives
WO1998030566A1 (fr) 1997-01-06 1998-07-16 Pfizer Inc. Derives de sulfone cyclique
WO1998033768A1 (fr) 1997-02-03 1998-08-06 Pfizer Products Inc. Derives d'acide arylsulfonylaminohydroxamique
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
WO1998033798A2 (fr) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3d]pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
WO1998034915A1 (fr) 1997-02-07 1998-08-13 Pfizer Inc. Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
WO1998034918A1 (fr) 1997-02-11 1998-08-13 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
WO1998050356A1 (fr) 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
US6524347B1 (en) 1997-05-28 2003-02-25 Avantis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6528526B1 (en) 1997-05-28 2003-03-04 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6482834B2 (en) 1997-05-28 2002-11-19 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6696434B2 (en) 1997-05-28 2004-02-24 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
WO1998054093A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
WO1999007701A1 (fr) 1997-08-05 1999-02-18 Sugen, Inc. Derives de quinoxaline tricyclique utiles en tant qu'inhibiteurs de proteine tyrosine kinase
WO1999007675A1 (fr) 1997-08-08 1999-02-18 Pfizer Products Inc. Derives de l'acide aryloxyarylsulfonylamino hydroxamique
WO1999010349A1 (fr) 1997-08-22 1999-03-04 Zeneca Limited Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
WO1999016755A1 (fr) 1997-09-26 1999-04-08 Merck & Co., Inc. Nouveaux inhibiteurs de l'angiogenese
WO1999024440A1 (fr) 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
US5932580A (en) 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
WO1999029667A1 (fr) 1997-12-05 1999-06-17 Pfizer Limited Derives d'acide hydroxamique utilises comme inhibiteurs de metalloproteases matricielles
WO1999032620A1 (fr) 1997-12-22 1999-07-01 Forssmann Wolf Georg Fragments de proteine liant le facteur de croissance de substances apparentees a l'insuline et leur utilisation
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6080769A (en) 1997-12-30 2000-06-27 Pfizer Inc. Imidazolidin-4-one derivatives useful as anticancer agents
WO1999035132A1 (fr) 1998-01-12 1999-07-15 Glaxo Group Limited Composes heterocycliques
WO1999035146A1 (fr) 1998-01-12 1999-07-15 Glaxo Group Limited Composes heteroaromatiques bicycliques agissant comme inhibiteurs de la tyrosine kinase
EP0931788A2 (fr) 1998-01-27 1999-07-28 Pfizer Limited Inhibiteurs de la métalloprotéinase
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
WO1999052889A1 (fr) 1998-04-10 1999-10-21 Pfizer Products Inc. Hydroxamides de l'acide (4-arylsulfonylamino)-tetrahydropyrane-4-carboxylique
WO1999052910A1 (fr) 1998-04-10 1999-10-21 Pfizer Products Inc. Derives bicycliques de l'acide hydroxamique
WO1999060023A1 (fr) 1998-05-15 1999-11-25 Imclone Systems Incorporated Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
WO1999061422A1 (fr) 1998-05-29 1999-12-02 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
US20020072589A1 (en) 1998-06-01 2002-06-13 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
WO1999063086A2 (fr) 1998-06-01 1999-12-09 Celtrix Pharmaceuticals, Inc. Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide
US6235764B1 (en) 1998-06-04 2001-05-22 Pfizer Inc. Isothiazole derivatives useful as anticancer agents
WO1999062890A1 (fr) 1998-06-04 1999-12-09 Pfizer Products Inc. Derives isothiazole utiles en tant qu'agents anticancereux
US6495564B1 (en) 1998-08-27 2002-12-17 Pfizer Inc. Quinolin-2-one derivatives useful as anticancer agents
US6150377A (en) 1998-08-27 2000-11-21 Pfizer Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
WO2000015781A1 (fr) 1998-09-11 2000-03-23 Eli Lilly And Company Antagonistes du facteur de croissance des fibroblastes
WO2000017203A1 (fr) 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines utilisees comme inhibiteurs de proteines kinases
WO2000023469A2 (fr) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments du facteur de croissance proche de l'insuline et de la proteine de fixation du facteur de croissance proche de l'insuline, et utilisations de ces fragments
EP1004578A2 (fr) 1998-11-05 2000-05-31 Pfizer Products Inc. Dérivés d'hydroxamide de l'acide 5-oxo-pyrrolidine-2-carboxylique
US6194438B1 (en) 1998-12-02 2001-02-27 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
WO2000035455A1 (fr) 1998-12-15 2000-06-22 Telik, Inc. Urees heteroaryle-aryle utilisees comme antagonistes du recepteur igf-1
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6465449B1 (en) 1999-01-27 2002-10-15 Pfizer Inc. Heteroaromatic bicyclic derivatives useful as anticancer agents
US6541481B2 (en) 1999-01-27 2003-04-01 Pfizer Inc Substituted bicyclic derivatives useful as anticancer agents
WO2000046380A2 (fr) 1999-02-08 2000-08-10 Chiron Corporation Fusion du recepteur du facteur de croissance des fibroblastes avec une immunoglobuline
US6258824B1 (en) 1999-02-11 2001-07-10 Pfizer Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
WO2000071129A1 (fr) 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazines inhibiteurs de kinases
US20060148748A1 (en) 1999-07-29 2006-07-06 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
WO2001032653A1 (fr) 1999-11-04 2001-05-10 Cephalon, Inc. Pyrazolones heterocycliques substitues
US6358954B1 (en) 1999-11-09 2002-03-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
US6673798B2 (en) 1999-11-09 2004-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
WO2001034574A1 (fr) 1999-11-11 2001-05-17 Osi Pharmaceuticals, Inc. Polymorphe stable de chlorhydrate de n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, et methodes de production et utilisations pharmaceutiques dudit polymorphe
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
US6596735B1 (en) 1999-11-30 2003-07-22 Pfizer Inc Quinoline derivatives useful for inhibiting farnesyl protein transferase
WO2001040217A1 (fr) 1999-11-30 2001-06-07 Pfizer Products Inc. Nouveaux derives benzoimidazole convenant comme agents antiproliferatifs
US6479513B2 (en) 2000-01-21 2002-11-12 Pfizer Inc. Anticancer compound and enantiomer separation method useful for synthesizing said compound
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
WO2001070977A2 (fr) 2000-03-22 2001-09-27 Amgen, Inc. Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations
US6537988B2 (en) 2000-03-27 2003-03-25 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer
WO2001072751A1 (fr) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
WO2002012238A2 (fr) 2000-08-04 2002-02-14 Warner-Lambert Company 2-(4-pyridyl)amino-6-dialcoxyphenyl-pyrido[2,3-d]pyrimidine-7-ones
US7037487B2 (en) 2000-09-27 2006-05-02 Sitke Aygen Method for diagnosing lactose intolerance and diagnostic kit for performing the method
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
WO2002092599A1 (fr) 2001-05-14 2002-11-21 Novartis Ag Derives 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US20030125370A1 (en) 2001-05-30 2003-07-03 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2002098914A2 (fr) 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Mutants de proteines de liaison du facteur de croissance insulinomimetique (igf) et methodes de production d'antagonistes
WO2002102804A1 (fr) 2001-06-19 2002-12-27 Axelar Ab Nouvelle utilisation de cyclolignans specifiques
WO2002102805A1 (fr) 2001-06-19 2002-12-27 Axelar Ab Nouvelle utilisation de cyclolignans et nouveaux cyclolignans
WO2002102973A2 (fr) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Anticorps bloquant l'activation de proteine tyrosine kinase recepteur, procedes de criblage et utilisations
WO2002102972A2 (fr) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Anticorps bloquant l'activation d'un recepteur a activite proteine tyrosine kinase, procedes de criblage et utilisations associes
US20040242603A1 (en) 2001-06-22 2004-12-02 Yasunari Fujiwara Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same
WO2003000660A1 (fr) 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive
WO2003013541A1 (fr) 2001-08-07 2003-02-20 Novartis Ag Derives de la 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine
WO2003015282A2 (fr) 2001-08-10 2003-02-20 Iroc Technologies Ensemble de circuits electroniques comportant des moyens de decontamination de parties contaminees par des erreurs
WO2003018021A1 (fr) 2001-08-22 2003-03-06 Amgen Inc. Derives pyrimidinyle 2,4-bisusbtitues utiles en tant qu'agents anticancereux
WO2003018022A1 (fr) 2001-08-22 2003-03-06 Amgen Inc. Derives de 2-amino-4-heteroarylaminopyrimidine pouvant etre utilises pour traiter le cancer
WO2003024967A2 (fr) 2001-09-19 2003-03-27 Aventis Pharma S.A. Composes chimiques
WO2003025019A1 (fr) 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anticorps anti-pdgf et procedes de production d'anticorps mis au point
WO2003035615A2 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
WO2003035619A1 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
WO2003035614A2 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
WO2003035616A2 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
WO2003048133A1 (fr) 2001-12-07 2003-06-12 Astrazeneca Ab Derives de pyrimidine utilises en tant que modulateurs du recepteur de du facteur 1 de croissance (igf-i) semblable a l'insuline
US20050009845A1 (en) 2001-12-19 2005-01-13 Caferro Thomas R. Thienopyrimidine compounds as protein tyrosine kinase inhibitors
WO2003068265A1 (fr) 2002-02-14 2003-08-21 Dana-Farber Cancer Institute Inc. Procedes et compositions pour traiter des etats hyperproliferatifs
WO2003078404A1 (fr) 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
WO2003087026A1 (fr) 2002-04-18 2003-10-23 F. Hoffmann-La Roche Ag 2-(2,6-dichlorophenyl)-diarylimidazoles
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
WO2003097641A2 (fr) 2002-05-21 2003-11-27 Novartis Ag Derives 1h-imidazo[4,5-c]quinoline servant au traitement de maladies dependant de proteines kinases
US20040018191A1 (en) 2002-05-24 2004-01-29 Schering Corporation Neutralizing human anti-IGFR antibody
WO2003099771A2 (fr) 2002-05-29 2003-12-04 Novartis Ag Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
WO2004001059A2 (fr) 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Inhibiteurs heterocycliques de kinases
WO2004005282A1 (fr) 2002-07-09 2004-01-15 Novartis Ag Derives de phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine
WO2004009601A1 (fr) 2002-07-19 2004-01-29 Bristol-Myers Squibb Company Inhibiteurs de l'azaindole kinase
WO2004009784A2 (fr) 2002-07-19 2004-01-29 Bristol-Myers Squibb Company Nouveaux inhibiteurs de kinases
WO2004013145A1 (fr) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Composes de pyrrolotriazine inhibiteurs de kinase
WO2004018472A2 (fr) 2002-08-14 2004-03-04 F. Hoffmann-La Roche Ag Composes pyrimido presentant une activite antiproliferative
US20040110758A1 (en) 2002-10-01 2004-06-10 Player Mark R. 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
WO2004041822A1 (fr) 2002-11-04 2004-05-21 F. Hoffmann-La Roche Ag Derives de pyrimido[4,5-d]pyrimidine a activite anticancereuse
WO2004046152A1 (fr) 2002-11-18 2004-06-03 F. Hoffmann La Roche Ag Diazyinopyrimidines
US6949563B2 (en) 2003-01-06 2005-09-27 Graham Michael Wynne (2-carboxamido)(3-amino)thiophene compounds
US20050154014A1 (en) 2003-01-06 2005-07-14 Jason Bloxham (2-carboxamido)(3-amino) thiophene compounds
US20040202651A1 (en) 2003-02-13 2004-10-14 Pfizer Inc. Uses of anti-insulin-like growth factor 1 receptor antibodies
US20050009840A1 (en) 2003-02-26 2005-01-13 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
WO2004076412A2 (fr) 2003-02-26 2004-09-10 Sugen, Inc. Composes d'aminoheteroaryle utilises en tant qu'inhibiteurs de proteine kinase
US20040198750A1 (en) 2003-04-03 2004-10-07 Jeremy Green Compositions useful as inhibitors of protein kinases
US20040204427A1 (en) 2003-04-10 2004-10-14 Yi Chen Pyrimido compounds having antiproliferative activity
WO2004093812A2 (fr) 2003-04-22 2004-11-04 Irm Llc Composes induisant une differentiation neuronale dans des cellules souche embryonnaires
WO2005004808A2 (fr) 2003-07-02 2005-01-20 Sugen, Inc. Composes tetracycliques utilises comme inhibiteurs de c-met
US20060009493A1 (en) 2003-07-02 2006-01-12 Sugen, Inc. Indolinone hydrazides as c-Met inhibitors
US20050075340A1 (en) 2003-07-02 2005-04-07 Sugen, Inc. Triazolotriazine compounds and uses thereof
WO2005017107A2 (fr) 2003-07-18 2005-02-24 Amgen Inc. Agents de liaison specifiques se liant a un facteur de croissance hepatocyte
WO2005011597A2 (fr) 2003-07-29 2005-02-10 Irm Llc Composes et compositions utilises en tant qu'inhibiteurs des proteines kinases
WO2005012359A2 (fr) 2003-08-01 2005-02-10 Genentech, Inc. Anticorps anti-vegf
WO2005016382A1 (fr) 2003-08-04 2005-02-24 Pfizer Products Inc. Anticorps diriges contre c-met
US7371378B2 (en) 2003-08-13 2008-05-13 Pfizer Inc. Modified human IGF-IR antibodies
US20050101650A1 (en) 2003-08-15 2005-05-12 Alex Aronov Pyrrole compositions useful as inhibitors of c-Met
WO2005021531A1 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs d'un ensemble de benzimidazolyle c n substitue
WO2005021537A1 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs de c-kit pyrazolyle-amidyle-benzimidazolyle n-substitues
WO2005021544A2 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
WO2005028448A1 (fr) 2003-09-12 2005-03-31 Merck Patent Gmbh Derives de benzyl-benzimidazolyle
US20050148574A1 (en) 2003-09-24 2005-07-07 Alex Aronov Imidazole compositions useful as inhibitors of protein kinases
WO2005030140A2 (fr) 2003-09-26 2005-04-07 Exelixis, Inc. Modulateurs de c-met et procede d'utilisation
US7192738B2 (en) 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
WO2005037836A2 (fr) 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazopyrazines utilisees comme inhibiteurs de la tyrosine kinase
US7408043B2 (en) 2003-11-11 2008-08-05 National Cancer Center Neutralizing antibody against HGF
US20050136063A1 (en) 2003-11-21 2005-06-23 Schering Corporation Anti-IGFR antibody therapeutic combinations
WO2005054246A2 (fr) 2003-12-04 2005-06-16 Merck Patent Gmbh Derives d'amine
WO2005066211A2 (fr) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Utilisation des recepteurs 1, 2, 3 et 4 du facteur de croissance des fibroblastes comme cibles pour une intervention therapeutique
US20050245547A1 (en) 2004-01-23 2005-11-03 Tae-Seong Kim Compounds and methods of use
WO2005070891A2 (fr) 2004-01-23 2005-08-04 Amgen Inc Composes et leurs procedes d'utilisation
WO2005080393A1 (fr) 2004-02-14 2005-09-01 Irm Llc Composes et compositions tenant lieu d'inhibiteurs de la proteine kinase
US20060235031A1 (en) 2004-04-02 2006-10-19 Arnold Lee D 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
US20060009453A1 (en) 2004-05-07 2006-01-12 Geuns-Meyer Stephanie D Protein kinase modulators and method of use
WO2005121125A1 (fr) 2004-06-09 2005-12-22 Pfizer Inc. Composes heteroaryle a liaison ether
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006014325A2 (fr) 2004-07-02 2006-02-09 Exelixis, Inc. Modulateurs de c-met et leur methode d'utilisation
WO2006015371A2 (fr) 2004-08-05 2006-02-09 Genentech, Inc. Antagonistes anti-cmet humanises
WO2006021886A1 (fr) 2004-08-26 2006-03-02 Pfizer Inc. Composes aminoheteroaryles en tant qu'inhibiteurs des proteines tyrosine kinases
WO2006021881A2 (fr) 2004-08-26 2006-03-02 Pfizer Inc. Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase
WO2006042599A1 (fr) 2004-10-13 2006-04-27 Merck Patent Gmbh Derives de phenyluree
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
WO2006050779A1 (fr) 2004-11-10 2006-05-18 Merck Patent Gmbh Derives de la n,n'-diphenyluree convenant comme inhibiteurs de kinases
WO2006050800A1 (fr) 2004-11-10 2006-05-18 Merck Patent Gmbh Derives de 4-amino-5-oxo-8-phenyl-5h-pyrido[2,3-d]-pyrimidine utilises en tant qu'inhibiteurs des tyrosines kinases et des kinases raf pour traiter des tumeurs
WO2006094600A1 (fr) 2005-03-10 2006-09-14 Merck Patent Gmbh Derives de tetrahydro-pyrrolo-quinoleine substitues servant de modulateurs de kinase, plus specialement de tyrosine kinases et de raf-kinases
WO2006105844A1 (fr) 2005-04-04 2006-10-12 Merck Patent Gmbh Derive de pyrazole
WO2006108482A1 (fr) 2005-04-14 2006-10-19 Merck Patent Gmbh Dérivés de purine en tant qu'inhibiteurs de l'activité de tyrosine kinase réceptrice
WO2006112479A1 (fr) 2005-04-19 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. Composé hétérocyclique azoté
WO2006134989A1 (fr) 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. Composé hétérocyclique azoté
WO2007009773A1 (fr) 2005-07-21 2007-01-25 Novartis Ag Derives de pyrazolo[1,5a]pyrimidin-7-yl-amine utilises en tant qu'inhibiteurs des proteines kinases
WO2007014123A2 (fr) 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions et procedes de traitement de maladies a l'aide de proteines de fusion fgfr
WO2007017107A1 (fr) 2005-07-29 2007-02-15 System Plast S.P.A. Chaîne en métal pour convoyeurs à chaîne
WO2007019884A1 (fr) 2005-08-16 2007-02-22 F. Hoffmann-La Roche Ag Nouveaux amides de l'acide 4-amino-thiéno[3,2-c]pyridine-7-carboxylique
WO2007063816A1 (fr) 2005-11-30 2007-06-07 Toray Industries, Inc. Pâte de verre, procédé de fabrication d'un afficheur en utilisant celle-ci et afficheur
WO2007103308A2 (fr) 2006-03-07 2007-09-13 Array Biopharma Inc. Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation
WO2007126799A2 (fr) 2006-03-30 2007-11-08 Novartis Ag Compositions et procédés d'utilisation associés à des anticorps de c-met
WO2007115049A2 (fr) 2006-04-01 2007-10-11 Galaxy Biotech, Llc Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes
WO2007143098A2 (fr) 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
US20110262525A1 (en) 2006-12-13 2011-10-27 Schering Corporation Methods of treatment
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
WO2009002521A2 (fr) 2007-06-25 2008-12-31 Amgen Inc. Compositions d'agents de liaison spécifiques vis-à-vis du facteur de croissance des hépatocytes
WO2009007427A2 (fr) 2007-07-12 2009-01-15 Pierre Fabre Medicament Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci
WO2009099982A1 (fr) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. Inhibiteurs de 2-aminopyridine kinases
WO2009100282A1 (fr) 2008-02-06 2009-08-13 Osi Pharmaceuticals, Inc. Furo-[3,2-c]pyridines et thiéno[3,2-c]pyridines
US20090226443A1 (en) 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and egfr antagonists
WO2010059771A1 (fr) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Pyrrolo[2,3-b]-pyridines et pyrrolo[2,3-b]-pyrazines substituées
US20110224191A1 (en) * 2008-11-20 2011-09-15 OSI Pharmaceuticals, LLC Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines
WO2011109593A1 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC 5-aminopyrrolo/pyrazolopyridines substituées
WO2011143645A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinase bicycliques fusionnés

Non-Patent Citations (127)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences, 18th edition", 1990, MACK PUBLISHING COMPANY
A. ALBERT ET AL., CHEM. BIOL. PTERIDINES PROC. INT. SYMP., 4TH, vol. 4, 1969, pages 1 - 5
ABSTRACTS OF THE 116TH ANNUAL MEETING OF THE PHARMACEUTICAL SOCIETY OF JAPAN (KANAZAWA), vol. 2, 1996, pages 275
ALBERT, A. ET AL., JOURNAL OF THE CHEMICAL SOCIETY, vol. 11, 1970, pages 1540 - 1547
BASERGA R., EXP. CELL. RES., vol. 253, 1999, pages 1 - 6
BEAN J; BRENNAN C; SHIH JY ET AL.: "MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib", PROC NATL ACAD SCI USA, vol. 104, no. 52, 2007, pages 20932 - 7, XP002566375, DOI: doi:10.1073/PNAS.0710370104
BIRCHMCICR, C., NAT REV MOL CELL BIOL, vol. 4, 2003, pages 915 - 925
BIRCHMEIER, C. ET AL., NAT REV MOL CELL BIOL, vol. 4, 2003, pages 915 - 925
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423
BOCCACCIO C; SABATINO G; MEDICO E ET AL.: "The MET oncogene drives a genetic programme linking cancer to haemostasis", NATURE, vol. 434, no. 7031, 2005, pages 396 - 400, XP002428579, DOI: doi:10.1038/nature03357
BREMMELKAMP, T.R. ET AL., SCIENCE, vol. 296, 2002, pages 550 - 553
BREVET M ET AL: "Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy", JOURNAL OF THORACIC ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, PA, US, vol. 6, no. 5, 1 May 2011 (2011-05-01), pages 864 - 874, XP008162890, ISSN: 1556-0864, DOI: 10.1097/JTO.0B013E318215A07D *
BRIDGES, EXP. OPIN. THER. PATENTS, vol. 5, 1995, pages 1245
BROWN ERIC ET AL: "Combination treatment strategy of an IGF-1R kinase inhibitor, OSI-906, in models of progressive disease following initial response to EGFR tyrosine kinase inhibitor therapy", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING; 100TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; DENVER, CA, USA; APRIL 18 -22, 2009, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 50, 1 April 2009 (2009-04-01), pages 419, XP001539735, ISSN: 0197-016X *
BUCHDUNGER ET AL., PROC. NAT. ACAD. SCI. (USA), vol. 92, 1995, pages 2558
BUCK E; EYZAGUIRRE A; BARR S ET AL.: "Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition", MOL CANCER THER, vol. 6, no. 2, 2007, pages 532 - 41, XP002506469, DOI: doi:10.1158/1535-7163.MCT-06-0462
BUCK E; EYZAGUIRRE A; HALEY JD; GIBSON NW; CAGNONI P; IWATA KK: "Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity", MOL CANCER THER, vol. 5, no. 8, 2006, pages 2051 - 9, XP002484511, DOI: doi:10.1158/1535-7163.MCT-06-0007
BUCK E; EYZAGUIRRE A; ROSENFELD-FRANKLIN M ET AL.: "Feedback mcchanisms promote coopcrativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors", CANCER RES, vol. 68, no. 20, 2008, pages 8322 - 32
BUCK E; GOKHALE PC; KOUJAK S ET AL.: "Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor- receptor (IGF-1R): rationale for cotargeting IGF-IR and IR in cancer", MOL CANCER THER, vol. 9, no. 10, 2010, pages 2652 - 64, XP009147487, DOI: doi:10.1158/1535-7163.MCT-10-0318
BUCK, E.; MULVIHILL, M., EXPERT OPIN. INVESTIG. DRUGS, vol. 20, no. 4, 2011, pages 605 - 621
BUERGER, C. ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 37610 - 37621
BUERGER, C.; GRONER, B., J. CANCER RES. CLIN. ONCOL., vol. 129, no. 12, 2003, pages 669 - 675
CAMIRAND, A. ET AL., BREAST CANCER RESEARCH, vol. 7, 2005, pages R570 - R579
CAMIRAND, A.; POLLAK, M., BRIT. J. CANCER, vol. 90, 2004, pages 1825 - 1829
CAMIRAND, A.; POLLAK, M.: "Brit. J. Cancer", vol. 90, 2004, PFIZER INC., pages: 1825 - 1829
CANCER RES., vol. 54, 1994, pages 6106 - 6114
CAO ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 29461 - 29467
CAO ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 22924 - 22928
CARBONI J M ET AL: "BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR", MOLECULAR CANCER THERAPEUTICS 2009 AMERICAN ASSOCIATION FOR CANCER RESEARCH INC. USA, vol. 8, no. 12, December 2009 (2009-12-01), pages 3341 - 3349, XP055032374, ISSN: 1535-7163 *
CARBONI, J.M. ET AL., MOL CANCER THER, vol. 8, no. 12, 2009, pages 3341 - 3349
CECCHI F; RABE DC; BOTTARO DP: "Targeting the HGF/Met signalling pathway in cancer", EUR J CANCER, vol. 46, no. 7, pages 1260 - 70
CHEN, C-H. B. ET AL., PROC. NATL. ACAD. SCI., vol. 100, 2003, pages 9226 - 9231
CHRISTENSEN ET AL., CANCER RES., vol. 63, 2003, pages 7345 - 7355
CODONY-SERVAT J ET AL: "Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 5, no. 3, 1 March 2006 (2006-03-01), pages 665 - 675, XP002599501, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-05-0147 *
COMOGLIO PM; GIORDANO S; TRUSOLINO L.: "Drug development of MET inhibitors: targeting oncogene addiction and expedience", NAT REV DRUG DISCOV, vol. 7, no. 6, 2008, pages 504 - 16, XP002565003, DOI: doi:10.1038/nrd2530
COOPER CS; PARK M; BLAIR DG ET AL.: "Molecular cloning of a new transforming gene from a chemically transformed human cell line", NATURE, vol. 311, no. 5981, 1984, pages 29 - 33
COOPER, C. S. ET AL., NATURE, vol. 311, 1984, pages 29 - 33
CUI, J.J., EXPERT OPIN. THER. PATENTS, vol. 17, no. 9, 2007, pages 1035 - 1045
DAI ET AL., GENES & DEV., vol. 15, 2001, pages 1913 - 25
DANCEY, J.; SAUSVILLE, E.A., NATURE REV. DRUG DISCOVERY, vol. 2, 2003, pages 92 - 313
DANILKOVITCH-MIAGKOVA, A.; ZBAR, B., J CLIN INVEST, vol. 109, 2002, pages 863 - 867
DOLLE ET AL., J. MED. CHEM., vol. 37, 1994, pages 2627
EDER J.P. ET AL., CLIN CANCER RES 2009, vol. 15, no. 7, 1 April 2009 (2009-04-01)
ELBASHIR, S.M. ET AL., NATURE, vol. 411, 2001, pages 494 - 498
EMERGING DRUGS: THE PROSPECT FOR IMPROVED MEDICINES, 1996, pages 241 - 260
ENDOCRINOLOGY, vol. 138, 1997, pages 1427 - 1433
ENGELMAN JA; MUKOHARA T; ZEJNULLAHU K ET AL.: "Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 116, no. 10, 2006, pages 2695 - 706, XP002498404, DOI: doi:10.1172/JCI28656
ENGELMAN JA; ZEJNULLAHU K; MITSUDOMI T ET AL.: "MET amplification leads to gcfitinib resistance in lung cancer by activating ERBB3 signaling", SCIENCE, vol. 316, no. 5827, 2007, pages 1039 - 43, XP002498405, DOI: doi:10.1126/science.1141478
FAHAM, S. ET AL., CURR. OPIN. STRUCT. BIOL., vol. 8, 1998, pages 578 - 586
FAN, Q-W ET AL., CANCER CELL, vol. 9, 2006, pages 341 - 349
FERRY RJ ET AL.: "Insulin-like growth factor binding proteins: new proteins, new functions.", HORM. RES., vol. 51, no. 2, 1999, pages 53 - 67
FRAZIER, CURR. OPIN. CELL BIOL., vol. 3, 1991, pages 792
FREDERICK BA; HELFRICH BA; COLDREN CD ET AL.: "Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma", MOL CANCER THER, vol. 6, no. 6, 2007, pages 1683 - 91, XP007909848, DOI: doi:10.1158/1535-7163.MCT-07-0138
FURGE KA; ZHANG YW; VANDE WOUDE GF: "Met receptor tyrosine kinase: enhanced signaling through adapter proteins", ONCOGENE, vol. 19, no. 49, 2000, pages 5582 - 9, XP001205225, DOI: doi:10.1038/sj.onc.1203859
GALZIE, Z. ET AL., BIOCHEM. CELL. BIOL., vol. 75, 1997, pages 669 - 685
GARCIA-ECHEVERRIA, C. ET AL., CANCER CELL, vol. 5, 2004, pages 231 - 239
GHERARDI, E. ET AL., NATURE REVIEWS, CANCER, vol. 12, 2012, pages 89 - 103
GOLDSTEIN ET AL., CLIN. CANCER RES., vol. 1, 1995, pages 1311 - 1318
GUALBERTO A; POLLAK M: "Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions", ONCOGENE, 2009
GUIX M; FABER AC; WANG SE ET AL.: "Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins", THE JOURNAL OF CLINICAL INVESTIGATION, 2008
HANNON, G.J., NATURE, vol. 418, 2002, pages 244 - 251
HUANG, S. M. ET AL., CANCER RES. 15, vol. 59, no. 8, 15 December 1998 (1998-12-15), pages 1935 - 40
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879
IBRAHIM, Y.H.; YEE, D., CLIN. CANCER RES., vol. 11, 2005, pages 944S - 950S
JI QS; MULVIHILL MJ; ROSENFELD-FRANKLIN M ET AL.: "A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo", MOL CANCER THER, vol. 6, no. 8, 2007, pages 2158 - 67
JO M; STOLZ DB; ESPLCN JE; DORKO K; MICHALOPOULOS GK; STROM SC: "Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells", J BIOL CHEM, vol. 275, no. 12, 2000, pages 8806 - 11
JONES, J.I.; D.R. CLEMMONS, ENDOCRINE REV., vol. 16, 1995, pages 3
KELLEY, K.M. ET AL., INT. J. BIOCHEM. CELL BIOL., vol. 28, 1996, pages 619
KIM K J ET AL., CLIN CANCER RES., vol. 12, no. 4, 2006, pages 1292 - 8
KNIGHT, Z.A. ET AL., CELL, vol. 125, 2006, pages 733 - 747
KONG-BELTRAN, M ET AL., CANCER CELL, vol. 6, no. 1, 2004, pages 75 - 84
KUHN DEBORAH J ET AL: "Blockade of IGF-1R with OSI-906 Overcomes Bortezomib-Resistance in Multiple Myeloma", vol. 118, no. 21, 1 November 2011 (2011-11-01), pages 421, XP008162884, ISSN: 0006-4971, Retrieved from the Internet <URL:http://www.bloodjournal.org/> *
LARSSON, O. ET AL., BRIT. J. CANCER, vol. 92, 2005, pages 2097 - 2101
LEE JJ; CHU E.: "First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer", CLIN COLORECTAL CANCER, vol. 6, no. 2, 2007, pages 42 - 6
LEROITH D; ROBERTS CT, JR: "The insulin-like growth factor system and cancer", CANCER LETT, vol. 195, no. 2, 2003, pages 127 - 37
LEVITZKI A.: "EGF receptor as a therapeutic target", LUNG CANCER, vol. 41, 2003, pages S9 - 14
LIANG TJ; REID AE; XAVIER R; CARDIFF RD; WANG TC: "Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 97, no. 12, 1996, pages 2872 - 7, XP002968390, DOI: doi:10.1172/JCI118744
LUTTERBACH B; ZENG Q; DAVIS LJ ET AL.: "Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival", CANCER RES, vol. 67, no. 5, 2007, pages 2081 - 8, XP055164255, DOI: doi:10.1158/0008-5472.CAN-06-3495
LYNCH TJ; BELL DW; SORDELLA R ET AL.: "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N ENGL J MED, vol. 350, no. 21, 2004, pages 2129 - 39
MA ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 2312 - 2319
MAGGIORA ET AL., J. CELL PHYSIOL., vol. 173, 1997, pages 183 - 186
MAGUIRE ET AL., J. MED. CHEM., vol. 37, 1994, pages 2129
MANO M; HUMBLET Y: "Drug Insight: panitumumab, a human EGFR- targeted monoclonal antibody with promising clinical activity in colorectal cancer", NATURE CLINICAL PRACTICE, 2008
MARTENS, T ET AL., CLIN CANCER RES, vol. 12, 2006, pages 6144
MCCAIG ET AL., BR. J. CANCER, vol. 86, 2002, pages 1963 - 1969
MCMANUS, M.T.; SHARP, P. A., NATURE REVIEWS GENETICS, vol. 3, 2002, pages 737 - 747
MITSIADES, C.S. ET AL., CANCER CELL, vol. 5, 2004, pages 221 - 230
MIYAMOTO, S. ET AL., CLINICAL CANCER RESEARCH, vol. 11, 2005, pages 3494 - 3502
MODJTAHEDI, H. ET AL., BR. J. CANCER, vol. 67, 1993, pages 247 - 253
MOORE M.: "Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer.", ASCO ANNUAL MEETING PROCEEDINGS; 2005, 2005
MORGILLO F; WOO JK; KIM ES; HONG WK; LEE HY: "Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib", CANCER RESEARCH, vol. 66, no. 20, 2006, pages 10100 - 11, XP002680948, DOI: doi:10.1158/0008-5472.CAN-06-1684
MOYER, J.D. ET AL., CANCER RES., vol. 57, 1997, pages 4838 - 4848
MULVIHILL MJ; BUCK E.: "Royal Society of Chemistry Drug Discovery Series 2011", article "The discovery of OSI-906, a small-molecule inhibitor of the insulin-like growth factor- and insulin receptors"
MULVIHILL MJ; COOKE A; ROSENFELD-FRANKLIN M ET AL.: "Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor", FUTURE MEDICINAL CHEMISTRY, vol. 1, no. 6, 2009, pages 1153 - 71, XP009147529
NAKAJIMA, M. ET AL., CANCER, vol. 85, pages 1894 - 1902
NAKAMURA T; MATSUMOTO K; KIRITOSHI A; TANO Y; NAKAMURA T: "Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions", CANCER RES, vol. 57, no. 15, 1997, pages 3305 - 13
O'REILLY, M. S. ET AL., CELL, vol. 79, 1994, pages 315 - 328
O'REILLY, M. S. ET AL., CELL, vol. 88, 1997, pages 277
PERKS ET AL., BIOCHIM. BIOPHYS. RES. COMM., vol. 294, 2002, pages 988 - 994
PESCHARD P; PARK M: "From Tpr-Met to Met, tumorigenesis and tubes", ONCOGCNC, vol. 26, no. 9, 2007, pages 1276 - 85, XP055203423, DOI: doi:10.1038/sj.onc.1210201
POLLAK M.: "Insulin and insulin-like growth factor signalling in neoplasia", NAT REV CANCER, vol. 8, no. 12, 2008, pages 915 - 28
RAJARAM S ET AL.: "Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions.", ENDOCR. REV., vol. 18, no. 6, 1998, pages 801 - 31
RODON ET AL., MOL. CANCER THER., vol. 7, no. 9, 2008, pages 2575 - 2588
ROSKOSKI R, JR.: "The ErbB/HER receptor protein-tyrosine kinases and cancer", BIOCHEM BIOPHYS RES COMMUN, vol. 319, no. 1, 2004, pages 1 - 11, XP004509841, DOI: doi:10.1016/j.bbrc.2004.04.150
SCHILLER JH; AKERLEY WL; BRUGGER W ET AL.: "Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC", J CLIN ONCOL, vol. 28, 2010, pages 18S
SHEPHERD FA; RODRIGUES PEREIRA J; CIULEANU T ET AL.: "Erlotinib in previously treated non-small-cell lung cancer", N ENGL J MED, vol. 353, no. 2, 2005, pages 123 - 32
SHERWOOD ET AL., PROC. AM. ASSOC. CANCER RES., vol. 40, 1999, pages 723
SORDELLA R; BELL DW; HABER DA; SETTLEMAN J: "Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways", SCIENCE, vol. 305, no. 5687, 2004, pages 1163 - 7, XP002447438, DOI: doi:10.1126/science.1101637
SPADA; MYERS, EXP. OPIN. THER. PATENTS, vol. 5, 1995, pages 805
SPAGNOLI, A.; R.G. ROSENFELD, CURR. OP. ENDOCRINOLOGY AND DIABETES, vol. 4, 1997, pages 1
TAKAYAMA, H. ET AL., PROC NATL ACAD SCI USA, vol. 94, 1997, pages 701 - 706
TERAMOTO, T. ET AL., CANCER, vol. 77, 1996, pages 639 - 645
THOMSON S; BUCK E; PETTI F ET AL.: "Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition", CANCER RES, vol. 65, no. 20, 2005, pages 9455 - 62, XP002391562, DOI: doi:10.1158/0008-5472.CAN-05-1058
THOMSON S; PETTI F; SUJKA-KWOK I ET AL.: "A systems view of epithelial-mesenchymal transition signaling states", CLINICAL & EXPERIMENTAL METASTASIS, vol. 28, no. 2, pages 137 - 55, XP019882903, DOI: doi:10.1007/s10585-010-9367-3
TRAXLER, P., EXP. OPIN. THER. PATENTS, vol. 8, no. 12, 1998, pages 1599 - 1625
TURKE AB; ZEJNULLAHU K; WU YL ET AL.: "Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC", CANCER CELL, vol. 1 7, no. L, pages 77 - 88
TUSCHI, T. ET AL., GENES DEV., vol. 13, no. 24, 1999, pages 3191 - 3197
WANG X ET AL: "Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells", CANCER INVESTIGATION, MARCEL DEKKER INC, US, vol. 30, no. 9, 1 November 2012 (2012-11-01), pages 657 - 662, XP008162883, ISSN: 0735-7907, DOI: DOI:10.3109/07357907.2012.725442 *
WARD, NATURE, vol. 341, 1989, pages 544
WOODBURN ET AL., PROC. AM. ASSOC. CANCER RES., vol. 38, 1997, pages 633
YANG, X. ET AL., CANCER RES., vol. 59, 1999, pages 1236 - 1243
YANG, X.D. ET AL., CANCER RES., vol. 59, 1999, pages 1236 - 43
YAUCH RL; JANUARIO T; EBERHARD DA ET AL.: "Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients", CLIN CANCER RES, vol. 11, 2005, pages 8686 - 98
ZHANG H; YEE D: "The therapeutic potential of agents targeting the type I insulin-like growth factor receptor", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 13, no. 12, 2004, pages 1569 - 77, XP008048792, DOI: doi:10.1517/13543784.13.12.1569
ZIMMERMAN ET AL., BIORG. MED. CHEM. LETT., vol. 6, 1996, pages 1221 - 1226
ZIPPCL ET AL., EUR. J. CELL BIOL., vol. 50, no. 2, 1989, pages 428 - 34
ZWILLCR ET AL., ONCOIZENE, vol. 6, 1991, pages 219 - 21

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869668B2 (en) 2014-08-26 2018-01-16 Samsung Electronics Co., Ltd. PDGF as a biomarker for predicting resistance or effect of c-Met targeting drugs
US10064939B2 (en) 2014-11-21 2018-09-04 Samsung Electronics Co., Ltd. Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers
US11142578B2 (en) 2016-11-16 2021-10-12 Regeneron Pharmaceuticals, Inc. Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
WO2022115946A1 (fr) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Applications thérapeutiques d'antagonistes du récepteur du facteur de croissance de type insuline 1 (igf-1)

Similar Documents

Publication Publication Date Title
US20090263397A1 (en) Combination anti-cancer therapy
RU2601892C2 (ru) Комбинированная терапия антагонистами с-мет и egfr
US11879013B2 (en) Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US8575164B2 (en) Combination cancer therapy
US20090274698A1 (en) Combination anti-cancer therapy
BR112019011410A2 (pt) métodos para tratar um paciente tendo câncer, para aumentar uma população da célula efetora imune pró-inflamatória, para aumentar o nível de ativação de célula t, para reduzir a população de células t reguladoras, para inibir a função imunossupressora das células t reguladoras, para o realce de longa duração da geração das células t de memória específicas de tumor e para proteger as células imunológicas intratumorais da quimioterapia.
EP2776042B1 (fr) Polythérapie médicamenteuse pour le traitement de tumeurs solides
WO2013152252A1 (fr) Polythérapie antinéoplasique
US20120189641A1 (en) Combination anti-cancer therapy
KR102439911B1 (ko) 제약학적 복합제제
ES2922314T3 (es) Compuestos heterocíclicos condensados como inhibidores de cinasa RET
AU2014254057A1 (en) Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
López-Calderero et al. The insulin-like growth factor pathway as a target for cancer therapy
WO2006081985A1 (fr) Traitement combine par un derive de n4-(oxycarbonyl substitue)-5&#39;-desoxy-5-fluorocytidine et un inhibiteur de l&#39;activite kinase du recepteur du facteur de croissance epidermique
AU2010236818B2 (en) Combination therapy using an anti-EGFR agent(s) and IGF-1R specific inhibitors
US20070286864A1 (en) Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
US20090136517A1 (en) Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
KR20150127203A (ko) Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
RU2779478C2 (ru) Сохранение иммунного ответа во время химиотерапевтических схем
WO2007146226A2 (fr) Traitement combiné avec un inhibiteur d&#39;egfr kinase et un agent qui sensibilise les cellules tumorales aux effets des inhibiteurs d&#39;egfr kinases
JP2023518508A (ja) 腫瘍を治療するための抗ｈｅｒ２抗体とｃｄｋ阻害剤の組み合わせ
CA3140360A1 (fr) Polytherapies avec des anticorps anti-egfr/c-met bispecifiques et des inhibiteurs de tyrosine kinase egfr de troisieme generation
JP2015503568A (ja) トラスツズマブに不応性の乳癌の治療方法
Warner et al. Emerging Molecular Targets in the Treatment of Head and Neck Squamous Cell Carcinoma
CN117098537A (zh) 用于癌症治疗的联合疗法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13717391

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13717391

Country of ref document: EP

Kind code of ref document: A1